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Background: People with an intellectual (learning) disability (ID) and epilepsy have an increased seizure
frequency, higher frequencies of multiple antiepileptic drug (AED) use and side effects, higher treatment
costs, higher mortality rates and more behavioural problems than the rest of the population with epilepsy.
The introduction of nurse-led care may lead to improvements in outcome for those with an ID and
epilepsy; however, this has not been tested in a definitive clinical trial.
Objective: To determine whether or not ID nurses, using a competency framework developed to optimise
nurse management of epilepsy in people with an ID, can cost-effectively improve clinical and quality-of-life
outcomes in the management of epilepsy compared with treatment as usual.
Design: Cluster-randomised two-arm trial.
Setting: Community-based secondary care delivered by members of community ID teams.
Participants: Participants were adults aged 18–65 years with an ID and epilepsy under the care of a
community ID team and had had at least one seizure in the 6 months before the trial.
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Interventions: The experimental intervention was the Learning Disability Epilepsy Specialist Nurse
Competency Framework. This provides guidelines describing a structure and goals to support the delivery
of epilepsy care and management by ID-trained nurses.
Main outcome measures: The primary outcome was the seizure severity scale from the Epilepsy and
Learning Disabilities Quality of Life questionnaire. Measures of mood, behaviour, AED side effects and
carer strain were also collected. A cost–utility analysis was undertaken along with a qualitative examination
of carers’ views of participants’ epilepsy management.
Results: In total, 312 individuals were recruited into the study from 17 research clusters. Using an
intention-to-treat analysis controlling for baseline individual-level and cluster-level variables there was no
significant difference in seizure severity score between the two arms. Altogether, 238 complete cases were
included in the non-imputed primary analysis. Analyses of the secondary outcomes revealed no significant
differences between arms. A planned subgroup analysis identified a significant interaction between
treatment arm and level of ID. There was a suggestion in those with mild to moderate ID that the
competency framework may be associated with a small reduction in concerns over seizure severity
(standard error 2.005, 95% confidence interval –0.554 to 7.307; p = 0.092). However, neither subgroup
showed a significant intervention effect individually. Family members’ perceptions of nurses’ management
depended on the professional status of the nurses, regardless of trial arm. Economic analysis suggested
that the competency framework intervention was likely to be cost-effective, primarily because of a
reduction in the costs of supporting participants compared with treatment as usual.
Limitations: The intervention could not be delivered blinded. Treatment as usual varied widely between
the research sites.
Conclusions: Overall, for adults with an ID and epilepsy, the framework conferred no clinical benefit
compared with usual treatment. The economic analysis suggested that there may be a role for the
framework in enhancing the cost-effectiveness of support for people with epilepsy and an ID. Future
research could explore the specific value of the competency framework for those with a mild to moderate
ID and the potential for greater long-term benefits arising from the continuing professional development
element of the framework.
Trial registration: Current Controlled Trials ISRCTN96895428.
Funding: This trial was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 22, No. 10. See the NIHR Journals Library website
for further project information.
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Plain English summary
Adults with an intellectual disability (ID) have an intelligence quotient (IQ) of < 70 and serious limitationsin communication and the abilities required for many or all of the demands of everyday life. They also
have an increased risk of epilepsy compared with the rest of the population. The epilepsy experienced by
those with an ID tends to be more severe and more difficult to treat than epilepsy in those without an ID.
The aim of the Epilepsy And Intellectual Disability (EpAID) trial was to see whether or not making use of
the recently developed Learning Disability Epilepsy Specialist Nurse Competency Framework could improve
outcomes for adults with an ID and epilepsy compared with treatment as usual. A key aspect of this
framework is that it was designed to be used by all ID nurses, not just the small number of epilepsy nurse
specialists, and, therefore, if it is shown to be effective, it could be readily used across the NHS.
The trial took place in 17 community ID clinical teams across England, Scotland and Wales and involved
312 adults with an ID and epilepsy. Overall, the results of the trial indicated that, in terms of clinical
outcomes, the competency framework was no better than treatment as usual. For those with a mild or
moderate ID the results suggested that use of the framework may have been associated with a slight
reduction in the severity of their seizures, as noticed by somebody providing care for them.
The EpAID clinical trial is the first controlled trial to test the possible benefits of a nurse-led intervention
for epilepsy in adults with an ID. The economic analysis suggested that, in general, the competency
framework intervention resulted in a small reduction in quality of life but saved money.
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Scientific summary
Background
In adults with an intellectual disability (ID) and epilepsy there are suggestions that the introduction of
nurse-led care may lead to improvements in management. However, this has not been tested in a
definitive clinical trial and results cannot be generalised from general population studies as epilepsy tends
to be more severe and to be associated with additional clinical comorbidities in adults with ID. This trial
investigated whether or not ID nurses, instructed in the use of a competency framework developed to
optimise nurse management of epilepsy in people with an ID, can cost-effectively improve clinical and
quality-of-life (QoL) outcomes in the management of epilepsy within this population compared with
treatment as usual (TAU).
Methods and study design
The Epilepsy And Intellectual Disability (EpAID) clinical trial was a two-arm cluster randomised controlled trial
(RCT) of a competency framework designed to provide guidelines to inform the practice, training and
development of nurses involved in the management of antiepileptic drug (AED) resistant epilepsy in adults
with an ID, whatever their previous level of experience. Several competencies are addressed in the framework,
including the clinical diagnosis and management of epilepsy, assessing and managing risk, the impact of
epilepsy and multidisciplinary team working. The comparator condition was TAU. Clusters were randomly
assigned to either a TAU control arm or the competency framework active arm. In both arms participants
underwent 4 weeks of baseline data collection followed by a minimum of 24 weeks of intervention and
4 weeks of follow-up data collection. The primary outcome was a measure of seizure severity, including
associated injuries and the level of distress manifested by the patient, as perceived by an informant. Secondary
outcomes included an economic analysis, health-related QoL, carer strain, seizure frequency and side effects.
Descriptive measures included demographic and clinical descriptors of participants and clinical services in
which they were receiving their epilepsy management. A qualitative examination of clinical interactions and
carers’ views about participants’ epilepsy management during the trial was also undertaken.
Results
In total, 312 individuals were recruited into the study. Of the 17 research sites included in the trial,
eight were randomised to the framework intervention and nine to TAU. A total of 128 participants were
recruited in sites randomised to TAU and 184 were recruited in sites randomised to the competency
framework. Of those entered into the trial, 41 (13%) either withdrew from the trial (n = 35) or died (n = 6)
between the start of the baseline period and the end of the follow-up period.
The primary outcome measure employed to assess the effect of introducing the competency framework
was the Epilepsy and Learning Disabilities Quality of Life seizure severity scale (ELDQoL-SSS) score. Using an
intention-to-treat analysis controlling for baseline individual-level and cluster-level variables, there was no
significant difference in ELDQoL-SSS score between the two arms of the trial [mean difference –0.326,
95% confidence interval (CI) –4.382 to 3.731; p = 0.875). Likewise, in terms of the secondary outcomes,
there were no significant differences between the arms in the Epilepsy and Learning Disabilities Quality of
Life (ELDQoL) AED side effects scale score (0.194, 95% CI –2.981 to 3.369; p = 0.905), the ELDQoL
behaviour scale score (0.661, 95% CI –1.295 to 2.617; p = 0.508), the ELDQoL mood scale score (0.854,
95% CI –2.167 to 3.874; p = 0.580), the Modified Carer Strain Index score (–0.569, 95% CI –3.766 to
2.629; p = 0.727) or the number of tonic–clonic seizures (–3.143, 95% CI –8.823 to 2.537; p = 0.278).
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A planned subgroup analysis identified a significant interaction between treatment arm and level of ID for
the ELDQoL-SSS score (p = 0.018). However neither subgroup showed a significant intervention effect
individually [treatment effect for those with mild to moderate ID (n = 95): mean difference between
intervention and TAU 3.931 (95% CI –0.554 to 7.307; p = 0.092); treatment effect for severe to profound
ID (n = 185): mean difference –1.968 (95% CI –6.981 to 3.044; p = 0.442)].
The economic analysis suggested that the competency framework intervention was cost-effective.
The competency framework was associated with a reduction in monthly costs compared with TAU.
However, the data also indicated that the framework intervention was associated with a reduction in
QoL, although in all cases the effect associated with treatment was not significant at the 95% confidence
level. Hospital costs were limited to the costs associated with epilepsy. Overall, the data indicate that the
competency framework is likely to be cost-effective compared with usual care and that it is more likely to
be cost-effective in patients with a severe or profound ID. Despite this, qualitative analysis of family carers’
experiences of the nursing management received by participants during the intervention period revealed
no clear evidence of any difference between the arms with respect to the family carers’ perceptions of
the ability of nurses to communicate effectively with health and social care professions. Family members’
perceptions of the ability of nurses to manage the side effects of medications, appreciate the impact of
comorbid physical health problems and work with multidisciplinary teams all depended on the professional
or organisational status of the nurses, again regardless of which arm of the trial participants had been
randomised to.
Conclusions
The EpAID clinical trial is the first cluster RCT to test the possible benefits of a nurse-led intervention for
epilepsy in adults with an ID. It demonstrated that differences in outcomes between the competency
framework arm and the TAU arm were limited and associated with various degrees of uncertainty. For the
population of adults with an ID and epilepsy as a whole, the framework conferred no clinical benefit
compared with TAU. However, there was an indication that its use in those with a mild to moderate ID
may be associated with a small amount of benefit in terms of reducing concerns over seizure severity.
The economic analysis demonstrated that, in general, the competency framework intervention was
cost-effective. It resulted in a small reduction in QoL but generated cost savings that would justify its
introduction at currently accepted thresholds.
Nurses with experience in ID and epilepsy could be well placed to deliver or facilitate the epilepsy
management recommended by the relevant National Institute for Health and Care Excellence clinical
guidelines for adults with an ID. Future research will be able to explore the specific value of the
competency framework for those with a mild to moderate ID and the potential for greater long-term
benefits arising from application of the continuing professional development element of the framework.
Trial registration
This trial is registered as ISRCTN96895428.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Text in this chapter has been reproduced from Ring et al.1 © Ring et al. 2016. This article is distributedunder the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
A note on terminology
A number of terms are in use to describe the intellectual functioning of individuals with a significant
impairment of cognitive and other abilities arising from congenital, including genetic, disturbances of
development or from pathological processes arising during the developmental period. In this trial the
description ‘intellectual disability’ (ID) will be used. The other term still in common use to describe the
same population is ‘learning disability’ (LD). In both instances the heterogeneous group of conditions being
referred to are characterised by the presence of significant limitations in intellectual functioning, usually
considered to be equivalent to a measured intelligence quotient (IQ) of < 70, together with deficits in
social and adaptive behaviours, with onset during the developmental period (< 18 years of age).
Similarly, several terms are used to describe the training of nurses working with people with an ID.
These nurses will generally have undertaken a nursing course specifically developed for this field and may
describe themselves as either LD nurses or ID nurses.
With respect to experience and training in the field of epilepsy, again several terms are in use in the UK.
Epilepsy specialist nurses are individuals with a primary training in general and/or ID nursing who have
undertaken additional formal specialist training in epilepsy and its management. The great majority of
nurses working with people who have an ID and epilepsy have not undertaken the additional formal
specialist training that would lead to the title of epilepsy nurse specialist (ENS), but they will, in the course
of their training and practice, have gained some level of experience in epilepsy. This is quantified in the
Epilepsy And Intellectual Disability (EpAID) clinical trial by use of the competency framework that underpins
the experimental intervention. Thus, the majority of nurses delivering the intervention in the EpAID trial
were ID nurses with a level of expertise in epilepsy described by the framework. A small proportion,
however, met the criteria for ENSs.
Epilepsy and intellectual disability
Nearly one million adults in England have an ID; epilepsy is the most common medical illness in this group,
affecting around 26%, with higher rates in those with more severe IDs.2 Individuals with an ID and
epilepsy have a worse outcome than those in the general population with epilepsy, with an increased
seizure frequency, higher frequencies of multiple antiepileptic drug (AED) use and side effects, higher
treatment costs, higher rates of mortality and a greater incidence of behavioural problems.1,3–5
Reflecting these observations, it has been reported that, between 2005 and 2009, the most common
cause of avoidable acute hospital admission for people with an ID was seizures associated with poorly
controlled epilepsy.6 A survey by the Improving Health and Lives: Learning Disabilities Observatory reported
that the second most frequent potentially preventable cause of death in those with an ID was epilepsy or
convulsions (occurring in 13% of those with an ID).7 These observations highlight the need to improve
outcomes for people with epilepsy and an ID.
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Currently, in the UK, secondary care of epilepsy and IDs is generally provided by community ID services or
hospital-based neurological services.8 It is common for people with an ID to be on multiple therapies and
they are likely to have tried several AEDs to reduce seizure severity and frequency.3 Only around 30% of
this population will achieve seizure freedom, compared with 70% of the general population.1,4 Therefore,
in most people with epilepsy and an ID, the aim of treatment with AED is to reduce seizure severity and
frequency while keeping associated side effects to a minimum.9 Achieving this balance is often difficult
in adults with an ID because of the severity of the epilepsy and the frequent presence of complex
associated morbidities.
Associated morbidities of epilepsy in adults with an ID include motor and mobility problems, communication
difficulties, attentional deficits and a range of emotional, cognitive and behavioural problems.1 Therefore,
identifying and differentiating presenting symptoms from an individual’s ID, epilepsy and medication side
effects is often challenging.
Additional challenges are faced by treating clinicians in communicating effectively with people who
have an ID and comorbid communication difficulties and psychobehavioural conditions such as affective
disorders, autism or a range of challenging behaviours that limit their ability to co-operate with the
demands of treatment.3 Individuals with epilepsy and an ID also often lack the capacity to understand and
make decisions regarding their treatment, meaning that ‘best interest’ decisions may be required, often
involving tripartite discussion between the individual, his or her family members or paid carer and the
treating clinician.10 These challenges and the need for innovative approaches to overcome them were
recognised by Public Health England in their 2014 paper, Making Reasonable Adjustments to Epilepsy
Services for People with Learning Disabilities.11 These observations all indicate that a multidisciplinary,
holistic approach, supported by judicious use of specialist nursing input, may improve clinical management
for people with an ID and epilepsy, who historically have frequently been excluded from clinical research
and overlooked by health services.
The role of nurses with expertise in the management of epilepsy
Nurses with enhanced expertise in the management of epilepsy, often described as ENSs, offer a broad
spectrum of services to patients with epilepsy. Depending on their level of training and expertise they
contribute to activities that may include patient assessment, medication management and ordering and
interpreting investigations.12 They also provide education, support and counselling to patients and families,
which are often overlooked by other clinicians.13–15 ENSs may also have more time to speak to patients16
and may improve the continuity of, and accessibility to, care, with the potential to improve communication
between people with epilepsy and their primary health-care services.17,18 Thus, it might be predicted that
ENSs would be ideally placed to champion and enhance the unpredictable, complex and long-term needs
of people with epilepsy.19
However, a Cochrane review20 of five trials of the use of epilepsy specialist nursing found no convincing
evidence across the general population that ENSs improved overall outcomes for people with epilepsy.
Nevertheless, an open prospective survey of the effects of introducing paediatric ENSs, published after
the Cochrane review, suggested that paediatric ENSs might reduce emergency admissions by as much
as 50%.21
In terms of financial costs, a trial22 in patients recruited from a hospital-based epilepsy service, of whom
just under 10% had an ID, noted that the use of an epilepsy nurse cost less than standard care, with
reduced numbers of outpatient clinic hospital attendances with doctors and a potential decrease in general
practitioner (GP) consultations after 6 months.
The great majority of previous research into the use of ENSs has been carried out in the general
population, in studies that have largely or completely excluded adults with IDs, perpetuating the health
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
2
inequalities that people with IDs have been subject to. Advocacy organisations, especially Mencap,23
have highlighted examples of such inequalities in health care, noting that clinicians regularly fail people
with IDs by failing to consult with or involve parents and family members in care and treatment decisions.
In addition, and importantly, a survey of epilepsy services for a community sample of adults with an ID
and epilepsy24 found that only 34% of respondents had seen an ENS. This low exposure rate was found
despite indications that ENSs may enhance the care of people with an ID and epilepsy.25–27 For instance, an
open study28 demonstrated that implementing the National Institute for Health and Care Excellence (NICE)
epilepsy guidelines for people with an ID, including having a central role for an ENS, led to identifiable
improvements in patient care. However, that conclusion was based on an audit of just 23 patients.
Rationale for the trial
Some anecdotal evidence and data from open studies suggests that ENS-led management may improve
outcomes and reduce the costs of care for adults with epilepsy and an ID. However, this has not been
tested in a definitive clinical trial and the results from previous studies in the general population cannot
necessarily be generalised to adults with an ID, given the often greater severity and complexity of epilepsy
and associated morbidities in those with ID. In addition, the majority of previous research has examined
the role and effects of specific ENS interventions. However, as noted above, ENSs are a relatively rare
resource not accessed by the majority of adults with an ID and epilepsy. It is the case, however, that nurses
trained to work with people who have an ID also have experience and often some additional training in
the management of epilepsy. In the absence of data to clearly support or refute the value of nurse-led
epilepsy services for adults, either in the general population or among those with an ID, currently this
skilled, potentially clinically effective resource is utilised variably and inefficiently.29,30 The EpAID trial thus
aimed to determine whether or not the use of a nurse-led intervention was associated with clinically
effective and cost-effective benefits in the management of epilepsy in adults with an ID. Specifically, the
trial aimed to test the effectiveness of the recently developed Learning Disability Epilepsy Specialist Nurse
Competency Framework31 to improve outcomes for adults with an ID and epilepsy.
A key aspect of this framework is that it was designed to be applicable to the practice and professional
development of all ID nurses, not just the small number of ENSs. Thus, if the use of the framework by
nurses representative of those working in more or less all community intellectual disability team (CIDTs)
was found to be effective, it could be readily implemented across the NHS.
DOI: 10.3310/hta22100 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 10
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Ring et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
3

Chapter 2 Methods
Text in this chapter has been reproduced from Ring et al.1 © Ring et al. 2016. This article is distributedunder the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.
org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
Aim and objectives
The aim of this trial was to test the hypothesis that an ENS-led intervention would cost-effectively reduce
seizure severity and improve overall quality of life (QoL) for patients and those who provide care for them
in the community.
Primary objective
The primary objective of the trial was to establish whether or not nurses with a range of previous
experience in epilepsy and ID, reflecting the skill mix currently existing in the NHS, working in accord with
the Learning Disability Epilepsy Specialist Nurse Competency Framework,31 could improve epilepsy-related
clinical and QoL outcomes in the management of epilepsy in adults with an ID compared with treatment
as usual (TAU), as measured using the Epilepsy and Learning Disabilities Quality of Life seizure severity
scale (ELDQoL-SSS).32
Secondary objectives
The main secondary outcome was to establish whether or not any perceived benefits represent good value
for money after consideration of the costs associated with the intervention from the perspective of health
and social services. Additional secondary outcomes consisted of a measure of carer strain, the Epilepsy
and Learning Disabilities Quality of Life (ELDQoL) subscales for AED side effects, mood and behaviour and
semistructured interviews of samples of clinicians, family members and paid carers to examine how the
competency framework, compared with TAU, had an impact on relationships that are critical in delivering
ongoing care for adults with an ID and epilepsy.
Trial design
The study was a cluster randomised controlled trial (RCT) with two arms: a TAU control arm and an
experimental arm involving the use of the ID epilepsy nurse competency framework.31 The trial complied
with the Consolidated Standards of Reporting Trials (CONSORT) guidelines for cluster randomised trials.33
The study also contained a nested qualitative component. A cluster randomised design was selected
because the intervention, a change in how nurses worked within the community team setting, needed
to be implemented at the level of the clinical team as a whole. This was because, first, pilot work had
previously indicated that within a community team the nurses would share duties from time to time and
therefore all would need to follow the same treatment approach and, second, as the active intervention
also involved training of the nurses administering it, those nurses could no longer be considered to be able
to continue to deliver TAU reliably. The trial was therefore developed such that a community team
constituted a single cluster.
The design of the trial is shown in Figure 1. A flow diagram is provided in Figure 2, which describes the
order in which cluster and participant recruitment, cluster randomisation, data collection and intervention
processes at each research cluster took place.
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It is important to note that participant recruitment at a site was completed before the King’s Clinical Trials
Unit (KCTU) communicated which arm of the trial that site would be randomised to. The involvement of
participants in the trial commenced with a 4-week period of baseline observation; this was followed by a
minimum of 24 weeks of trial intervention, during which they received either TAU or care according to the
competency framework, after which they underwent a 4-week period of follow-up observations. The trial
intervention also continued during the follow-up phase.
Identify cluster sites
(community intellectual disability teams)
Identify all potentially eligible participants in each cluster.
Randomly select participants within each cluster
(aim of n = 320)
Randomly allocate clusters to active intervention or
treatment as usual control (randomisation by KCTU with
cluster informed after participant recruitment)
Contact 1: prepare participant
and carer to provide 4-week
baseline data
Contact 1: prepare participant
and carer to provide 4-week
baseline data
Contact 2: collect baseline
data – ELDQoL, seizure diary,
clinical data, CSRI, EQ-5D-5L and MCSI
Contact 2: collect baseline
data – ELDQoL, seizure diary,
clinical data, CSRI, EQ-5D-5L and MCSI
Collect outcome data over 
4 weeks, after at least 20 weeks
of active treatment; ELDQoL,
seizure diary, clinical data, CSRI,
EQ-5D-5L, MCSI, WTP and nested
qualitative component
Collect outcome data over 
4 weeks, after at least 20 weeks
of TAU; ELDQoL, seizure diary,
clinical data, CSRI, EQ-5D-5L, MCSI,
WTP and nested qualitative
component
Analyse results and
disseminate findings
Active intervention
(nurse working to competency
framework)
Control intervention
(TAU)
FIGURE 1 Design of the EpAID trial. CSRI, Client Service Receipt Inventory; EQ-5D-5L, EuroQol-5 Dimensions,
five-level version; KCTU, King’s Clinical Trial Unit; MCSI, Modified Caregiver Strain Index; WTP, willingness to pay.
This figure has been reproduced from Ring et al.1 © Ring et al. 2016. This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were
made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/)
applies to the data made available in this article, unless otherwise stated.
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Assignment of interventions
Randomisation of the clusters was undertaken independently by KCTU using block randomisation with
fixed block sizes. A minimum of two sites were randomised at a time to preserve allocation concealment.
Site details were submitted to KCTU after potential participants within the centre had been identified.
Cluster randomisation to treatment arm took place close to the start of the intervention phase to minimise
the risk of clusters withdrawing between randomisation and the start of the trial.
Enrolment
Allocation
Allocated to active intervention
(n = 184)
• Received allocated intervention, n = 183
• Did not received allocated intervention,
   n = 1 unable to contact
Lost to follow-up, n = 13 unable to contact
Discontinued intervention
• Died, n = 4
• Withdrew consent, n = 8
Lost to follow-up, n = 10 unable to contact
Discontinued intervention
• Died, n = 2
• Withdrew consent, n = 3
Randomised
(n = 312)
Assessed for eligibility
(n = 1726)
Follow-up
Analysis
• Received allocated intervention, n = 127
• Did not received allocated intervention,
   n = 1 withdrew during baseline
Allocated to TAU control
(n = 128)
Analysed
(n = 184)
• Excluded from analysis (give reasons), n = 0 • Excluded from analysis (give reasons), n = 0
Analysed
(n = 128)
           Excluded
           (n = 1414)
• Not meeting inclusion criteria, n = 865
• Declined to participate, n = 108
• Other reasons, n = 441
FIGURE 2 Flow diagram depicting the EpAID trial processes. This figure has been reproduced from Ring et al.1
© Ring et al. 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction
in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
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Concealment mechanism
The nature of the active intervention – a change in working protocols for the nurses delivering the
intervention – was such that the study could not be fully blind. However, the following measures were
taken to minimise the risk of bias being introduced.
l There was random selection of participants into the trial in each cluster and random allocation of each
cluster to treatment arm.
l To minimise expectations of the participants, their carers and families and the clinical staff at each cluster,
they were not informed that there were two arms in the trial (an ‘active’ arm and a TAU arm), nor were
they informed which arm of the study they had been randomised to. They were told instead about the
range of interventions included in the trial and that patient treatment may or may not change.
l The individual cluster sites were not informed what the intervention that they were to deliver should
look like until the month prior to the intervention phase and they were informed only after participant
recruitment at that site had been completed. As indicated above, the information provided to
participants and clusters included a degree of obfuscation around the design of the trial.
l As in the normal course of events, there are some changes from time to time in how epilepsy is
managed in an individual with continuing seizures; it was expected that this would blur, to some
extent, any perceived variations in management associated with the two arms of the study.
l The only people working on the trial who were informed which arm a cluster had been randomised
to were staff at KCTU undertaking the randomisation process and two senior nurse trainers who
provided training to the nurses delivering the trial interventions. The chairperson of the trial Data
Monitoring and Ethics Committee (DMEC) could also receive this information but only following a
specific request. Such a request was not in fact made during the trial. All other members of the
research team remained blind to which arm a cluster had been randomised to.
l The nurses delivering the treatment interventions were not present while members of the research
team collected baseline or follow-up data.
l The primary outcome measure and the majority of the secondary outcome measures took the form of
structured questionnaires and respondents were asked to consider their responses to these questions
before reporting them to the researchers collecting the data.
Participants
All participants were adults recruited from adult CIDTs. To be eligible to receive treatment from a CIDT an
individual needs to meet administrative criteria defining them as somebody with an ID. The criteria used in
the UK are described in Chapter 1, A note on terminology.
Eligibility criteria
Inclusion criteria
l Aged 18–65 years.
l The presence of a developmental ID with an IQ of ≤ 70.
l A diagnosis of epilepsy with a history of at least one seizure in the 6 months preceding recruitment
into the trial (not considered by those managing the epilepsy to have been a non-epileptic seizure).
l Nurse in the CIDT with a current role in delivering some aspects of epilepsy management at the time of
both screening and consent.
l Family carers, paid support workers and nurses were eligible for the semistructured interviews
comprising the qualitative element of the trial if they had participated in the trial and had indicated a
willingness to be approached for an interview.
METHODS
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Exclusion criteria
l The presence of a rapidly progressive physical or neurological illness.
l Alcohol or drug dependence.
The intervention
The experimental intervention was the Learning Disability Epilepsy Specialist Nurse Competency
Framework.31 This provides guidelines describing a structure and goals to support the delivery of epilepsy
care and management by LD-trained nurses. The guidelines were developed by the UK EpilepSy Nurses
Association (ESNA) in association with the UK Royal College of Nursing.
The competency framework provides a collection of competencies considered by the authors of the
framework to be central to effective clinical performance. It describes a series of interventions that can
be taken in clinical, educational and professional domains relevant to the optimal delivery of epilepsy
management in adults with an ID and epilepsy, tailored to the competency level of the nurse delivering the
interventions. The definitions and assessment of competency level, which are described in the competency
framework,31 are derived from Benner’s five-level model of nursing competence34 and enable all nurses
working in the field to be allocated to one of three levels of practice: ‘novice’, ‘competent’ and ‘expert’.
The framework itself, as described in the ESNA document,31 addresses the nine domains listed in Box 1.
For each of the nine domains, the specific actions that nurses should take at the appropriate level of
competence are split into performance criteria and the knowledge and understanding that would enable
these levels of performance. For example, under the domain of ‘assessing and managing linked health
conditions’, the following performance criteria are listed.
l For a novice nurse to:
¢ identify any common links between LD diagnosis and epilepsy prognosis
¢ carry out a basic health assessment, including developing health action plans
¢ discuss recognised LD conditions and syndromes linked to epilepsy
¢ demonstrate a basic understanding of the relationship between aetiology, diagnosis and prognosis
¢ complete health assessments
¢ direct the patient to their GP for an annual health check within an individual’s epilepsy management plan
l For a competent nurse to:
¢ demonstrate an understanding of the risk factors of developing epilepsy depending on the
patient’s LD syndromic classification, for example, Down Syndrome
¢ discuss the link between seizure control and physical ill-health
¢ take a written history which includes aetiology of LD, epilepsy syndrome, seizure diagnosis and
treatment neurological conditions
¢ discuss recognised epilepsy syndromes and potential impact on learning and development
¢ confidently discuss with others the evidence-based relationship between aetiology and diagnosis
with seizure presentation and treatment prognosis
¢ understand the potential link between physical ill health, seizure frequency and AEDs.
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BOX 1 The competencies described in the Learning Disability Epilepsy Specialist Nurse Competency Framework31
A. Clinical diagnosis and management of epilepsy.
I. Diagnosis of epilepsy.
II. Assessing and managing seizures.
(i) Assessing, planning, implementing and evaluating care.
III. Assessing and managing medicines.
(i) Antiepileptic drugs.
(ii) Emergency medication.
IV. Assessing and managing linked health conditions.
B. Assessing and managing risk.
C. Impact of epilepsy.
I. Assessing and managing the impact of epilepsy.
II. People with ID, families and carers.
D. Capacity and consent to treatment.
E. Personal planning and organisation.
I. Autonomy, accountability and management.
II. Telephone management relationships.
III. Time management.
F. Multidisciplinary team working.
G. Personal and professional development.
H. Evidence-based practice.
I. Development of educational programmes.
Adapted with permission from Doherty et al.31 (pp. 16–17). © 2013 ESNA. All rights reserved.
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l For an expert specialist nurse:
¢ to interpret and influence practice
¢ to assess the relationship between epilepsy and concomitant conditions, in particular chest
infection, dysphagia, sleep disorder, diabetes
¢ to assess the impact of epilepsy on the individual’s mental health status and/or behaviour
¢ to assess and record the impact of syndrome-specific features
¢ to assess and respond to the relationship between epilepsy and concomitant conditions
¢ to consider the overall impact of epilepsy in relation to specific conditions, which may be
exacerbated by seizures and or treatment and vice versa, and the health and well-being of
the individual
¢ to manage potential ill-health implications of long-term medication administration.
Reproduced with permission from Doherty et al.31 (p. 30). © 2013 ESNA
General guidance on how an individual nurse is placed at the appropriate level of competence is
provided in the competency framework (pp. 14–15).31 Each nurse’s competence was based on their own
self-rating of their level of competence on the following domains: clinical diagnosis and management
of epilepsy, impact of epilepsy, capacity and consent to treatment and multidisciplinary team working.
Competency was determined for each nurse delivering management at every site participating in the trial.
This determination took place during the trial-specific training received by each nurse shortly before the
end of the follow-up period at each site.
The activities undertaken by nurses delivering the intervention were recorded by them in a daily activity
diary for subsequent analysis (a copy of the diary template is provided in Appendix 1). The diaries provided
a record of the reasons for carrying out each intervention through the duration of the trial and the care
delivered during the interventions.
No potential treatments were precluded by being in the trial. A key element of the competency framework
is that it is not a manualised treatment guideline for epilepsy but rather a list of what management a
nurse should be able to deliver at their given level of competence. However, what management is actually
delivered will also depend on the way in which individual clinical services are arranged. Within these
constraints, nurses delivered their interventions at a frequency determined by clinical need, through home
visits, telephone clinics and visits to the local primary care or ID team base as appropriate. When nurses
considered that it was appropriate, and as described in the competency framework, they also delivered
epilepsy education to patients and carers. In addition, interactions with other clinicians, for example
participants’ primary care health service, local community ID health team and/or local neurology service,
were facilitated by the nurses as and when they considered clinically appropriate.
The control condition
The control condition was TAU. This was the existing management approach for each participant. As was
the case for the participants randomised to the competency framework arm, no potential treatments were
precluded by being in the trial. The activities undertaken by each nurse in the control arm when interacting
with any of the participants recruited into the trial in the control clusters were also recorded in a daily
activity diary for subsequent analysis.
Training of nurses delivering the active or control interventions
All of the nurses involved in delivering management to participants in the competency framework and TAU
arms received trial-specific training. This was led by two senior specialist nurses, experienced in nurse
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education, research and epilepsy. Nurses from both arms received training on the general principles
associated with undertaking a clinical trial, the eligibility criteria for participants in the EpAID trial and
how to complete the daily activity diary. In addition, each nurse had their competency level established
according to the three levels described in the competency framework, by discussing with the trainer their
level of expertise under each of the headings described in Box 1. The training was delivered at the nurses’
clinical base and staff from each cluster were trained separately.
For nurses in the TAU arm the training lasted for approximately 3 hours. Those nurses working in sites
allocated to the active intervention also received 3 hours of additional training specifically focusing on the
competency framework. This consisted of a workshop in which each of the competencies was considered
in detail, making use of guided discussion and reflections by each nurse on his or her own working
practices. The learning objectives for the competency-specific training were for each nurse to understand the
concept of nursing competencies, identify his or her individual level of expertise based on Benner’s nursing
competency framework,34 understand how the competency framework should be used in practice, explain
how competencies relate to the NHS Knowledge and Skills Framework35 and identify the competencies that
they should attain based on their level of expertise in relation to the diagnosis of epilepsy, classification of
epileptic seizures, assessing and managing seizures, assessing, planning, implementing and evaluating care,
collecting clinical information (seizure frequency, side effects, behavioural symptoms and effects of seizures
on daily life from patient and carers), assessing and managing the impact of epilepsy and QoL, working with
people with an ID, their families and carers, offering education, support and advice and directing to
additional services.
The training was provided by a nurse familiar with the competency framework and experienced in the
management of epilepsy in adults with IDs. The framework itself was used as the core text for the training.
A copy was given to each nurse and training was provided in how to make use of the framework
document for individual ongoing clinical practice and development.
For each cluster it was planned that the training would take place at the end of the baseline period.
At some sites, some nurses were trained earlier in the baseline period; when that happened for nurses in
the competency framework arm, they were asked by the trainer not to make use of the framework until
the intervention period started.
Trial setting
The trial took place within secondary care services in the community. Participants were recruited from
CIDTs and the trial interventions were delivered by telephone or in face-to face contact in participants’
homes or community day centres or in clinics held in CIDT bases by nurses working with the teams.
End points: definitions and acquisition
Primary end point
The primary end point was the ELDQoL-SSS32 (see Appendix 2). This was completed by carers and provided
a detailed measure of the carers’ views of the physical severity of seizures experienced by participants in
the preceding 4 weeks, including any associated injuries and the level of distress manifested by participants
after a seizure. Data were collected for 4 weeks at baseline, prior to the start of the intervention (time
point B2; Table 1) and again for 4 weeks after at least 24 weeks of intervention (time point F, see Table 1).
Possible scores ranged from 10 to 56, with higher scores indicating greater concerns of informants
regarding participants’ seizure severity. If a participant had no seizure during the preceding 4 weeks then
this was noted. In the statistical analysis of the seizure severity scale (SSS) scores, when a participant had
not had a seizure during the 4 weeks covered by the SSS, the lowest possible SSS score was imputed.
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TABLE 1 Study variables and trial procedure schedule
Form Content
Time point
Ongoing Withdrawal
Screening
(B1)
Baseline
(B2) Intervention
Follow-up
(F)
Registration
form
Year of birth, sex ✗
Demographics Epilepsy management,
ethnicity
✗
Eligibility form Inclusion/exclusion
criteria
✗
ELDQoL Individual items of each
ELDQoL subscale
✗ ✗ ✗
Epilepsy and ID
history form
Epilepsy history
(diagnosis, seizure type,
triggers), level of ID
✗
CSRI Accommodation, care
received
✗ ✗
MCSI Individual items of the
MCSI
✗ ✗
EQ-5D-5L Individual items of the
EQ-5D-5L
✗ ✗
Seizure diary
(for baseline
and follow-up)
Number of each type of
seizure (collected daily
for 4 weeks)
✗ ✗
Enrolment
form
Date of enrolment ✗
Seizure diary
(clinical)
Number of each seizure
type
✗
WTP Individual items of WTP ✗
Visit
information
Information about
visit (change of
accommodation, carer
present)
✗ ✗
Medication list Types of medication,
dose, frequency
✗ ✗
Serious adverse
event form
Date, seriousness,
effects, causality (related
to EpAID trial or not)
✗
Withdrawal
form
Date of and reason for
withdrawal from the
study
✗
Nurse
self-completion
activity diary
Date and time of visit,
location, reasons for
intervention, care given
✗
Clinical
information at
follow-up
✗
Nurse
registration
form
Nurse details (year of
birth, sex, cluster,
competence level)
✗
CSRI, Client Service Receipt Inventory; EQ-5D-5L, EuroQol-5 Dimensions, five-level version; MCSI, Modified Caregiver Strain
Index; WTP, willingness to pay.
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Secondary end points
Economic evaluation
This consisted of three separate but related evaluations. First, a cost-effectiveness analysis was undertaken
on the primary outcome measure of the trial, the ELDQoL-SSS score. Second, a cost–utility analysis was
undertaken after calculating changes in quality-adjusted life expectancy associated with the intervention,
derived from measurements of QoL captured using the EuroQoL-5 Dimensions, five-level version (EQ-5D-5L)36
(described in more detail in Economic analysis methodology). The EQ-5D-5L was collected at baseline and
after at least 24 weeks of intervention (time point F; see Table 1), to be used in conjunction with population
survey data to calculate quality-adjusted life-years (QALYs). Third, a cost–benefit analysis was undertaken for
the subset of patients living with a friend or relative in which the benefit of the intervention was assessed in
monetary terms. Resource use was captured using data recorded on a modified version of the Client Service
Receipt Inventory (CSRI)37 over a 4-week period at baseline (time point B2; see Table 1) and again for 4 weeks
after at least 24 weeks of intervention (time point F; see Table 1).
Carer preferences
Carer preferences were identified using willingness-to-pay (WTP) methods. Preferences were collected
from an adult with primary responsibility for the care of a participant using a questionnaire at follow-up
designed to elicit a monetary valuation of the intervention. Data were collected at least 24 weeks after
commencement of the intervention (time point F; see Table 1).
Number of seizures per month
The number of seizures per month was calculated from daily entries by participants’ carers in a seizure
diary. Seizure frequency data were collected to record the total number of tonic–clonic seizures and the
total number of all other seizures experienced by participants during a 4-week period at baseline (time
point B2; see Table 1) and again for a 4-week period after at least 24 weeks of intervention (time point F;
see Table 1).
Epilepsy and Learning Disabilities Quality of Life subscales for antiepileptic drug side
effects, mood and behaviour
These data were collected for 4 weeks at baseline, prior to the start of the intervention (time point B2;
see Table 1) and again for 4 weeks after at least 24 weeks of intervention (time point F; see Table 1).
The total possible scores ranged from 19 to 76 for the AED side effects profile, from 9 to 36 for the
behaviour scale and from 16 to 64 for the mood scale. For each of the subscales, higher scores indicate
poorer QoL/functioning.
Modified Caregiver Strain Index38
This instrument was employed to measure the possible effects of the intervention on emotional, financial
and practical stresses experienced by carers. The Modified Caregiver Strain Index (MCSI)38 was collected
in the baseline period and again after at least 24 weeks of intervention. The MCSI was collected only
from family respondents identified as a family member in response to question V6 of the relevant visit
information questionnaire [i.e. at baseline (time point B2; see Table 1) and follow-up (time point F;
see Table 1)]. Possible MCSI scores range from 0 to 26, with higher scores indicating a higher strain on
the carer.
A series of semistructured interviews with clinicians, family and paid carers
These interviews were conducted to examine how the competency framework, compared with TAU,
affected relationships between the nurses and family carers/paid support workers with respect to
(1) reported perceptions of patient health and QoL, (2) the involvement of patients in treatment decisions
and (3) the active engagement of carers with clinical epilepsy services. The interviews were conducted
by telephone. They lasted between 20 and 30 minutes and were audio recorded and transcribed.
METHODS
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The nurse self-completion daily activity diary
The nurse self-completion daily activity diary was completed throughout the trial by all of the nurses
delivering any intervention to any participant in either arm. These self-completion daily activity diaries
aimed to provide a reliable account of epilepsy-related nursing activity on a daily basis and at relatively
low cost.39 They have been used successfully as a data collection method in a number of studies,30,40,41
in which no difficulties were encountered in relation to attrition, missing data or failure to complete.
The diaries were prefaced with instructions for completion and a model example of how entries should
appear. Diary entry was expected to take each nurse approximately 15 minutes a day. For each visit, the
diaries were used to record the start and end time of the visit, where the visit took place (home, clinic,
general practice, by telephone, other), the reasons for intervention (1. assessment; 2. counselling;
3. education; 4. health facilitation; 5. management planning; 6. monitoring epilepsy; 7. monitoring
health/behaviour; 8. monitoring treatment; 9. responding to urgent health or behavioural concerns;
10. other) and details of the care given (1. education of family carer; 2. education of paid staff; 3. education
of patient; 4. health facilitation; 5. investigation request; 6. management planning; 7. medication issues;
8. prescribing; 9. review and monitoring of medication; 10. other). Multiple reasons for intervention and
details of care given at any given visit could be recorded.
Descriptive measures
The community intellectual disability team epilepsy service availability questionnaire
This was completed by psychiatric and nursing staff employed in each cluster. It was used to describe the
resources for epilepsy treatment available to the CIDTs locally at each cluster and the approach employed
in making use of these resources.
Demographic and clinical data
Demographic and clinical descriptors of participants were collected from participants’ clinical notes at
baseline. The descriptors included the level of ID (mild, moderate, severe, profound), the nature of their
accommodation (living alone, living with family, living in a group home or other community residential
care setting) (also collected at follow-up), sex, age, current antiepilepsy treatment (also collected at
follow-up) and any additional ID syndrome, psychiatric and neurological diagnoses.
Safety procedures and adverse events
The approach to defining, identifying and recording safety procedures and adverse events is described in
Appendix 3.
Data collection methods
The consenting of participants and the collection of baseline and follow-up data were undertaken either
by research assistants employed by the University of Cambridge or by Clinical Research Network (CRN)
nurses employed at the cluster sites. Consent was always obtained face to face. The majority of the data
were collected over the telephone by research assistants from family carers or paid support workers who
knew the participants well. The informants were sent the questionnaires in advance and their answers
were noted by a research assistant during a prearranged telephone conversation. Qualitative interviews
were conducted by telephone and audio recorded for later transcription. A WTP health economic
questionnaire was collected over the telephone during the follow-up phase.
The trial employed an electronic case report form (eCRF) created by KCTU in collaboration with the
trial statistician and the chief investigator using the MACRO Electronic Data Capture system (version 4;
InferMed, London, UK) and maintained by KCTU. It was hosted on a dedicated secure server within
KCTU’s host academic institution. The system is regulatory compliant42–44 with a full audit trail,
data discrepancy functionality and database lock functionality and supports real-time data cleaning
and reporting.
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Clinical outcome analyses
Analyses were undertaken to assess the efficacy of the use of the competency framework in comparison to
TAU in reducing the severity of seizures and improving QoL outcomes and to provide a measure of how
cost-effective this intervention was.
Primary efficacy analysis
The primary analysis assessed the efficacy of ENS-led care in comparison to TAU in reducing the severity of
seizures. The primary analysis was an intention-to-treat (ITT) analysis and the primary outcome was the
difference in ELDQoL-SSS score between baseline and follow-up. Because the trial was cluster randomised
and a clustering effect was expected, a linear mixed-effects model was fitted. Random effects to model
the effect of cluster were included. Baseline patient-level covariates included were ELDQoL-SSS score,
age, level of ID (mild, moderate, severe or profound), number of tonic–clonic seizures per month, living
circumstances (living independently, living with family members or living in a group home) and deprivation
index of cluster area. Cluster-level covariates included were mean seniority level across the cluster of the
nurses working in the cluster, to investigate possible therapist effects, and mean caseload of the nurses
working in the cluster. Multiple imputation (MI) was performed when > 3% of the covariates were missing.
The null hypothesis was that the treatment effect is zero. The alternative hypothesis was that there is
a difference in the change in ELDQoL-SSS score from baseline to follow-up between the competency
framework arm and the TAU arm. A Wald test for the effect of the intervention was used in the
primary analysis.
The following planned exploratory subgroup analyses were performed:
l interaction between treatment and number of seizures
l interaction between treatment and number of seizure types (one seizure type, more than one
seizure type)
l interaction between treatment and level of ID (mild/moderate, severe/profound)
l interaction between treatment and living circumstances (group home, with family members,
independently, other)
l interaction between treatment and baseline ELDQoL-SSS score (above the median, below the median)
l interaction between change in MCSI score and baseline number of tonic–clonic seizures.
Secondary outcomes were analysed using a suitable mixed-effects model (linear mixed-effects model
for continuous outcomes and a Poisson generalised linear mixed-effects model for count data) or by
accounting for the clustering using robust Huber–White standard errors. Secondary clinical end points
included the change in MCSI score, the number of seizures and the change in other subscales of the
ELDQoL (AED side effects, mood and behaviour). The covariates used for the analysis of the secondary
outcomes were the same as those included for the primary outcome measure. Each secondary end
point was analysed including its baseline value as a covariate.
Derived variables
The methods used to convert the individual items on each ELDQoL subscale into a total subscale score are
provided in Appendix 4. The 13 individual items on the MCSI can be scored as 0, 1 or 2. To obtain the
total MCSI score the sum of the individual items is calculated. When half or fewer than half of the MCSI
items were missing, the total MCSI score was calculated as the mean of the present items multiplied by
the total number of items in the instrument. If more than half of the items were missing the score was set
as ‘missing’.
The primary outcome of the trial – the difference in ELDQoL-SSS score – was calculated as the follow-up
ELDQoL-SSS score minus the baseline ELDQoL-SSS score. The secondary outcomes of MCSI score, number
of seizures per month and ELDQoL subscale scores for AED side effects, mood and behaviour were also
METHODS
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calculated by subtracting baseline values from follow-up values. The outcome of number of seizures per
month included the number of tonic–clonic seizures rather than the total number of seizures. This figure
was used as earlier pilot work had demonstrated that the recorded frequency of tonic–clonic seizures is
relatively reliable but that counts of other seizure types, such as focal seizures, absence seizures or atonic
seizures, are less so, as the phenomena in question may be either missed (on account of a very brief
duration or subtle manifestation) or misdiagnosed.
The variable age was derived using the date of the visit and the year of birth. The exact date of birth was
not recorded and so date of birth was assumed to be 30 June in the year of birth.
The competence level of the nurses was scored as follows: novice = 1, competent = 2 and expert = 3.
An overall nurse competence score for each cluster was calculated by taking the mean competence score
for all of the nurses who worked with the trial participants in that cluster. For example, if a cluster had
three novice, six competent and five expert nurses, the nurse competence score for the cluster was 2.14.
The caseload of the nurses in each cluster was calculated as the mean number of patients that each nurse
working in a cluster was treating.
The deprivation index involved ranking all of the postcodes, with the most deprived postcode being given
a ranking of 1. Postcodes were ranked within England, Scotland and Wales and so the ranks are not
comparable. The deprivation index was therefore converted into a categorical variable ranging from 1 to 5
based on the quintiles of the ranks, with the most deprived 20% of areas given a score of 1 and the least
deprived 20% given a score of 5. It should be noted that, although quintiles are more directly comparable
than ranks, they may still differ across countries because of differences in poverty between countries.
Assessment of treatment delivered (as recorded in the nurse activity diaries) was analysed as follows.
Summary statistics for the duration of the visits and where the visits took place were produced by arm.
The absolute number of visits by arm was calculated for each reason for intervention and details of
the care given are provided. The proportion of visits by arm was also calculated for each reason for
intervention and details of the care given are provided.
Sample size calculation
As this was a cluster randomised trial, the true value of the intraclass correlation coefficient (ICC)
would have a large impact on the power of the trial. Data from an earlier observational study of epilepsy
management in adults with an ID45 were used to estimate the ICC for the ELDQoL-SSS. The estimated ICC
was close to 0, but with a wide confidence interval (CI). We chose to power the study for the change in
ELDQoL-SSS score between baseline and follow-up at 24 weeks assuming an ICC of 0.05, which was
above the estimated value in the earlier observational study. The estimated standard deviation (SD) for the
change in ELDQoL-SSS score from this observational study was 6.55.
When planning the trial we originally aimed to recruit 12 clusters (six in each arm) of 30 patients to
provide 90% power at a one-sided 0.025 significance level to detect a true mean intervention effect
of 3.6. However, because of a lower than expected number of eligible patients per cluster, we modified
the trial’s sample size to assume 15 patients per cluster. In this case, 16 clusters (eight in each arm) would
provide 90% power at a one-sided 0.025 significance level using the same SD, target effect size and
ICC value.
Timing of the analyses
The final analyses were performed after the collection of follow-up data from all of the clusters and after
data cleaning and locking had taken place.
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Analysis population
The primary and all secondary end points were analysed using all of the participants in each cluster who
were randomised to the competency framework intervention or to TAU, who were not lost to follow-up.
Safety population
Safety data were analysed using all of the participants who received either the competency framework
intervention or TAU for any length of time. Participants who dropped out before receiving either treatment
were excluded.
Missing data
Covariate data
The primary analysis included participants in whom the outcome was observed. As a linear mixed-effects
model was used, missing outcome data were dealt with using a missing at random (MAR) assumption.
When > 3% of data for covariates were missing, MI was used for the primary analysis. Five imputations
were used unless the percentage missingness was greater than this. In this case, the number of
imputations was equal to the percentage missingness (e.g. if 10% of participants were missing baseline
data, we would use 10 imputations).
Outcome data
A further analysis was performed in which missing primary outcome data were imputed. Because of the
way that the ELDQoL-SSS was scored (see Appendix 4), there were a number of ways that the outcome
measure could be missing. These were if the participant:
1. was lost to follow-up
2. attended the visit but did not answer any questions on the ELDQoL-SSS
3. answered < 50% of the questions and therefore was defined as missing.
If a participant had no seizures in the previous month, he or she was unable to answer any of the
questions on the ELDQoL-SSS questionnaire and therefore the outcome was missing. In this case, the
missingness was informative of the outcome. When this was the reason for a missing baseline or follow-up
ELDQoL-SSS score the best possible score on the ELDQoL-SSS scale was imputed as it was assumed that no
seizures equates to a low seizure severity score. For this reason, the numbers of participants for whom the
outcome was missing (baseline and follow-up) are summarised by arm.
Secondary analyses
Multiple imputation was also performed on missing covariate and outcome data for all secondary clinical
analyses in a similar way to that performed for the primary analysis.
Economic analysis methodology
The analyses applied a health and social care perspective as the primary perspective, as recommended by
NICE.46 A societal perspective, which included additional costs falling on patients’ families, was applied in
sensitivity analyses.
Data collection for economic analyses
Resource use
We sought to collect data on all resource use relevant to the intervention, but to exclude resource use
unconnected to participants’ epilepsy or ID and hence unlikely to be influenced by the intervention.
In practice, it was impractical to assess all health or social care resource use for relevance to epilepsy/ID;
we did so only for hospitalisations when the risk was greatest for high-cost unrelated episodes to influence
METHODS
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the analysis. We used a modified version of the CSRI,47 which we had applied in a previous study of care
for adults with epilepsy and ID.8 The modified CSRI measured resource use relating to accommodation,
respite including holidays, primary health and social care, day care, secondary health care including
tests and investigations, mode of transport to health-care appointments and informal care. It asked
predominantly about the previous month, with the exception of respite care and holidays, in which the
relevant recall period was 6 months. In this, we sought to strike a balance between the accuracy of data
recall and the potential for seasonal differences to influence the results. In addition, data on medications
were collected separately.
Accommodation was recorded using one of four categories: group home, family home, independently
or other. The number of residents with special needs in the home was recorded. The number of nights of
respite care received and the provider of that respite care were recorded, along with the patient/family
contribution to the cost of respite care when applicable. The total number of nights spent on holiday over
the last 6 months was recorded, along with the patient/family contribution to the cost of holidays. The
numbers of contacts with doctors, nurses, allied health professionals and social workers in the last month
were recorded; contacts were categorised as home or office visits and the average duration of contact was
recorded. Data were collected on the provision of care assistance in the home, cleaning and laundry services
and Meals on Wheels, along with the duration of support when relevant and whether or not the patient
or family contributed to the cost. The numbers of visits to day centres, social clubs and drop-in centres,
attendance at adult education classes and miscellaneous activities were recorded. The miscellaneous
activities were further categorised as one-to-one or group activities. Hospital admissions were categorised
as accident and emergency (A&E) department visits, inpatient admissions, outpatient attendances or day
hospital attendances and respondents were asked to distinguish between care related to epilepsy and care
unrelated to epilepsy. Respondents were also asked to report the mode of transport that participants used
to travel to and from hospital. The numbers of radiography scans, electroencephalograms (EEGs), computed
tomography (CT) scans and magnetic resonance imaging (MRI) scans received by participants were
recorded. Finally, the CSRI included a section that quantified the hours of informal care provided along with
the occupation (and hence the potential market wage) of the primary carer (when applicable). This section
included further questions on the mode of transport that participants used to attend routine engagements.
Quality of life
Participant QoL was measured at baseline and follow-up using a condition-specific measure and a generic
measure. The condition-specific measure was the ELDQoL scale,32 described in End points: definitions
and acquisition. The generic measure was the EQ-5D-5L.48 This measure assesses health functioning
across five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
The five-level version elicits responses to each dimension at one of five levels, from no problems to
severe problems. The resulting responses are not simply summed; a ‘tariff’ or health state value for each
of the 3125 combinations of responses has been generated from a survey of the UK population.49
Questionnaires on QoL were completed by participants when feasible, with help from their primary carer,
or by the primary carer when necessary (proxy valuations). We did not attempt to distinguish between
patient and proxy valuations for two reasons. First, we considered that the dichotomisation of responses
would disguise a continuum of carer involvement in completion of the questionnaires, from modest
guidance to full, proxy completion. Second, the analysis considers the change in QoL rather than the
absolute value for each participant between baseline and follow-up. As a consequence, the impact of
proxy involvement is likely to be attenuated, assuming the same degree of involvement at baseline and
follow-up. Proxy valuations have been shown to be accurate for the physical aspects of health functioning,
but less so for the mental aspects.50
A cost–utility analysis was used to evaluate effectiveness. The cost–utility analysis enabled comparison
of cost-effectiveness against commonly accepted thresholds of acceptability in terms of the cost per
QALY gained.51 However, given the potential for a lack of sensitivity of the EQ-5D-5L to benefits of the
intervention for carers and for participants, we also undertook a cost–benefit analysis. The time horizon of
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each evaluation was 6 months and the primary perspective was health and social services. A broader
societal perspective was considered in sensitivity analyses.
Cost differences across the two arms of the trial were estimated using questionnaires assessing the
provision of health and social care at baseline and after 6 months and from time diaries completed by
ENSs. QALY gains were estimated as 0.5 × health-related QoL at 6 months after controlling for QoL at
baseline, ELDQoL-SSS score, age, level of ID, mean number of seizures per month (calculated as described
earlier) and living circumstances (as described earlier).
Willingness-to-pay data were collected from family carers but not paid support workers. They were collected
as open-ended responses with the use of prompt cards showing a range of values. Bootstrapping was used
to estimate uncertainty in mean costs and outcomes and to facilitate construction of cost-effectiveness
acceptability curves (CEACs) for the cost–utility analysis. Bootstrapping refers to a statistical technique used
to estimate uncertainty around a parameter without assuming a parametric distribution for the population
distribution of that parameter.
Monetary valuation of outcomes
When we could identify an informal carer with primary responsibility for a participant’s welfare, we sought
to elicit a monetary valuation of the benefit that he or she perceived from any changes in epilepsy-related
support from the nurse(s) working with that participant. At follow-up, carers in both trial arms were asked
if they thought that the support that they and the participant had received from their nurse had stayed
the same, improved or worsened. If they perceived that there had been a change, we sought a monetary
valuation of their preferred service in the form of the maximum monthly payment that they would be
prepared to make to maintain that service. We first presented respondents with a series of 13 payment
cards containing amounts varying from £1 to £1000 in random order and asked them to sort the cards
into amounts that they would pay, amounts that they would not pay and amounts for which they were
unsure whether or not they would pay. We then asked for the maximum that they would pay, with
prompting regarding the acceptable range indicated by the ‘card sort’.
We took reasonable steps to explain the purpose of the survey and emphasise that the exercise was purely
to value the care that participants had received and was not part of a process to determine an appropriate
charge for care. However, when respondents perceived a change in care but were unwilling to state a
payment value we sought to distinguish responses that indicated a value of zero from those that indicated
an unwillingness to provide a positive value (so called protest responses).52 Respondents who were
unwilling to state a value for the care that they had received were asked to select the reason why from a
menu of preset responses. The response ‘I do value the support I received but I believe the government
should pay for it’ was deemed to indicate a protest response (and hence a missing valuation). All other
responses were deemed to indicate a value of zero.
Data preparation for the economic analysis
Valuation of resource use
Unit costs for resource use were taken from three nationally relevant and recognised sources when
possible: NHS Reference Costs,53 Unit Costs of Health and Social Care (UCHSC)54 and the British National
Formulary.55 Unit costs for the financial year 2014/15 were applied. When necessary, costs were inflated
to 2014/15 prices using the Hospital and Community Health Services inflation index.54 Costs for primary
health and social care contacts were derived from the unit costs per patient contact hour reported in the
UCHSC combined with the relevant mean contact time reported by respondents. Only a cost per hour was
available for psychiatrists, psychologists and chiropodists. The unit cost was multiplied by 1.35 to estimate
the cost per patient contact hour. This figure was derived from the ratio of the cost per hour to the cost
per patient contact hour for consultant surgeons reported in an earlier version of the UCHSC.56 Costs per
contact hour for home visits were available in the UCHSC only for occupational therapists. We calculated
the ratio of the cost per patient contact hour between home visits and clinic visits for occupational
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therapists (1.158) and applied this to the relevant clinic visit costs to estimate the unit cost per patient
contact hour of home visits for all of the other health-care professionals.
A unit cost of care assistance at home of £24 per hour was taken from the UCHSC. A cost of £5.08
(after inflation) for each meal on wheels was derived from a Health Technology Assessment article.57 The
costs of a cleaner and laundry services were derived from online suppliers. The costs of day care including
one-to-one and group activities were taken from the UCHSC. Hospital A&E and outpatient visit and
day unit costs were taken from the UCHSC. An inpatient cost of £400 per bed-day was derived from
Department of Health estimates published in response to a freedom of information request.58 Unit costs
for tests and investigations were derived from NHS Reference Costs.53 Emergency ambulance and
passenger transport costs were derived from the UCHSC. Hospital car costs were estimated from a BBC
report on hospital expenditure on taxis.59
Informal care was valued at the gross market wage rate for carers when these data were available.
In the absence of data, or when carers were retired, informal care was valued at the legal minimum
wage rate for 2014/15 (£6.50 per hour from October 2014). Median gross market wage rates by
category of employment for 2015 were drawn from data published by the Office for National Statistics60
and converted to an hourly rate, assuming a working week of 32.2 hours.61 Estimation of car travel
costs assumed an 8-mile round trip for a visit by a nurse to a service user, costing 40p per mile.
Quantification of intervention benefits
Responses to the ELDQoL questionnaire at baseline and follow-up were scored according to the
recommended algorithms, which included imputing missing responses using the mean score for completed
questions for domains in which at least half of the questions had been completed (see Appendix 4).
Responses on the EQ-5D-5L at baseline and follow-up were scored using an algorithm published by
the EuroQoL group62 and based on a valuation exercise undertaken with a sample of the UK general
population.49 A missing score was recorded when responses to any of the five dimensions were missing.
We assumed that changes in QoL from baseline occurred quickly and that any differences in baseline and
follow-up QoL applied to the entire intervening period. QALYs were calculated as the product of time in
years and change in QoL. For example, an increase in QoL of 0.1 measured at 6 months from baseline
would equate to a QALY gain of 0.05 over that period.
A planned comparison of mean WTP values elicited at 6 months for participants in the intervention and
control arms was not undertaken because of the low number of responses.
Economic analysis
Regression analysis was used to determine the impact of treatment on costs and outcomes while controlling
for a prespecified list of baseline characteristics at participant and ENS level: baseline QoL (EQ-5D-5L
tariff), baseline SSS score (ELDQoL), baseline mood score (ELDQoL), baseline AED side effects profile score
(ELDQoL), baseline behaviour score (ELDQoL), costs in month prior to baseline, sex, age, number of
tonic–clonic seizures, ID level, neighbourhood deprivation score, nurse workload and nurse competence.
ID level entered the regression models as a categorical variable with four levels: mild, moderate, severe and
profound. A treatment*ID level interaction term was included to allow exploration of differential impacts
on the two subgroups of mild/moderate ID and severe/profound ID. The neighbourhood deprivation score
was determined as the Index of Multiple Deprivation derived from participants’ postcodes.63 Scores were
assigned to quintiles according to the relevant national ranking for England, Scotland or Wales. Nurse
competence was self-assessed at three levels: novice, competent and expert. The side effect profile score
was log-transformed to achieve a distribution that was closer to normal.
Generalised linear modelling was used to examine a range of potential distributions in modelling both costs
and EQ-5D-5L tariffs. The Park test64 was used to assess the suitability of alternative distributions and the
Hosmer–Lemeshow,65 Pregibon66 and Pearson67 tests were used to test the suitability of different link functions.
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Missing data were addressed using MI.68 Such an approach assumes that any data are MAR, that is,
missingness is random contingent on the observed data. Imputation was undertaken using chained equations.
Predictive mean matching was used for each variable with missing data to allow for non-normal distributions.69
Regression models were fitted across 20 imputations and the results were combined using Rubin’s rules to
estimate the incremental cost and incremental effectiveness attributable to treatment. The regression-adjusted
estimates of the treatment impact on costs and outcomes were used to express cost-effectiveness as the
incremental cost-effectiveness ratios (ICERs) for both QALYs and ELDQoL-SSS scores. ICERs were calculated as
the cost difference attributable to treatment, ΔC, divided by the difference in outcome, ΔE, attributable
to treatment:
ICER = ΔC/ΔE. (1)
Sampling uncertainty in the data was captured by bootstrapping. This ensured that any correlation in
costs and outcomes would be reflected in the distribution of cost-effectiveness estimates. A total of
1000 bootstrap replicates were created. Missing data were imputed using MI, with 20 imputations
undertaken on each bootstrap replicate. Regression models were fitted across the 20 imputations and the
results were combined using Rubin’s rules to estimate the incremental cost and incremental effectiveness
attributable to treatment. Thus, a single estimate for the impact of treatment on costs, SSS score and QoL
(EQ-5D-5L tariff) was derived for each bootstrap replicate after adjusting for baseline differences and
imputing missing data.
The bootstrap replicates were used to plot CEACs. For each bootstrap replicate the net monetary benefit
was calculated by multiplying the difference in outcomes attributable to treatment by a threshold value
and subtracting the difference in costs attributable to treatment. Calculations were undertaken for a range
of threshold values starting at £0. For each threshold value the proportion of the bootstrap replicates in
which the net monetary benefit was greater than £0 (treatment is cost-effective at that threshold) was
calculated. The CEAC could then be plotted as the proportion of bootstrap replicates with a positive net
monetary benefit (cost-effective) as a function of the threshold value. The threshold values were varied
from £0 to £50,000 per QALY and from £0 to £2000 per point on the SSS.
Sensitivity analyses
The primary economic analysis took a health and social care perspective as recommended by NICE.46
However, a considerable part of the care and support of adults with epilepsy and ID is likely to fall on their
family members. In the sensitivity analysis we considered a broader perspective, including costs falling on
participants or their family members and the impact of informal care. Transport, respite and holiday costs
falling on families were included. Informal care, valued as described in Valuation of resource use, was also
included. Cost-effectiveness was reported in the form of ICERs and CEACs generated from the bootstrap
replicates after inclusion of the additional costs.
Subgroup analysis according to ID level was undertaken by inclusion of a treatment*ID level interaction
term in the imputation and regression models. ID level was dichotomised into mild/moderate and severe/
profound. Missing data in the interaction term were imputed using the ‘just another variable’ approach
as recommended.70
Accommodation costs were large and subject to greater variation between baseline and follow-up in the
TAU arm than in the treatment arm. There was a possibility that inaccurate costing or changes unrelated
to the intervention might have driven the relative differences between the intervention arm and the TAU
arm. A sensitivity analysis was undertaken to examine health and social care costs and EQ-5D-5L tariff
values after excluding accommodation costs.
Finally, the analytical approach used, in which the data were bootstrapped and then imputed, did not
allow for explicit recognition of clustering by site in the bootstrap routine. A sensitivity analysis was
undertaken in which the data were first imputed (20 imputations) and then the differences in costs and
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outcomes between the intervention arm and the TAU arm were estimated on each imputation using a
two-stage bootstrap routine.71
Qualitative analysis methodology
The semistructured interviews were analysed using a systematic process of indexing and interpretation.
Answers to individual questions were summarised and then examined for content, with emergent themes
identified and coded.72 We examined how the competency framework, compared with TAU, affected
relationships between the ENSs and family members/paid carers with respect to (1) reported perceptions
of patient health and QoL, (2) the involvement of patients in treatment decisions and (3) the active
engagement of carers with clinical epilepsy services.
Trial governance
The trial was overseen by a Trial Steering Committee and a DMEC, both of which had an independent
chairperson. These committees were constituted and worked according to the research governance
guidelines issued by the National Institute for Health Research (NIHR)73 and the Medical Research Council.44
In addition, a Trial Advisory Group (TAG) was developed to provide ongoing public and patient observation
of the trial and advice. The TAG members included the mother of a young woman with a severe ID and
complex epilepsy, the manager of a community residential home for adults with an ID and epilepsy and
a representative from the charity Epilepsy Action who was also able to consult through that charity’s
volunteer and adviser contacts. The group considered and advised on issues relevant to recruitment
and the retention of participants, the outcome measures employed in the trial and the dissemination
of findings.
The trial safety procedures are described in Appendix 3.
Research ethics approvals
The trial received ethics approval for England and Wales from the National Research Ethics Service
(London Queen Square Committee) and for Scotland from the Scotland A Research Ethics Committee.
Amendments were reported to all study sites and the trial oversight committees. To enable inclusion of
adults lacking the capacity to decide whether or not to participate in research, appropriate approvals
were sought from family or care providers in line with sections 30–34 of the Mental Capacity Act 200574
(England and Wales) or section 51 of the Adults with Incapacity (Scotland) Act 2000.75
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Chapter 3 Results
Recruitment and attrition of participants
Figure 3 presents the CONSORT diagram describing the flow of potential participants through the trial.
In total, 312 individuals were recruited into the study. Of the 17 research sites included in the trial,
eight were randomised to the framework intervention and nine to TAU. A total of 128 participants were
recruited in sites randomised to TAU and 184 were recruited in sites randomised to the competency
framework. The numbers entering the trial at each site are provided in Table 2. Recruitment of research
Screen all patients vs.
EpAID criteria
Potential cluster identified
(ID team recruited if thought to
be supporting ≥ 50 adults with
ID and epilepsy)
Patients randomised by KCTU
Research team or network contact cluster patients
to explain trial and seek consent/assent
Randomised patients contacted
to obtain permission to send
their contact details to the
Trial Co-ordinating Centre 
Baseline data collection by
research team or network
Cluster randomisation
by KCTU
Intervention or TAU
Follow-up data collection
Identification
of clusters
Identification
of participants
Data collection
and
intervention
Treating nurses
receive trial-specific 
training relevant 
to arm
FIGURE 3 The EpAID trial CONSORT diagram. This figure has been reproduced from Ring et al.1 © Ring et al.
2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in
any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless
otherwise stated.
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sites into the trial was staggered, with the first site recruited in September 2014 and the final site recruited
in September 2015. Follow-up data collection was completed in October 2016.
The greatest attrition of potential participants from the total of those initially screened for eligibility arose as
a consequence of 50.1% of those screened not meeting the trial eligibility criteria. This is not surprising as
the screening populations used by the recruitment sites were all patients with an ID and epilepsy, whereas
the trial criteria required there to have been at least one seizure in the 6 months prior to the screening date,
thereby ruling out, by design, those whose seizures were well controlled. Of those who were considered
on screening to be eligible for the trial, there were three main causes of attrition: an inability to contact
potential participants during the recruiting window, accounting for 30% of those screened as eligible but
who did not proceed to enter the trial; no agreement from potential participants for their contact details to
be passed to the research team, accounting for 29% of those screened as eligible who did not proceed
to enter the trial; and refusal by the participant (or their consultee) to agree to participate in the trial,
accounting for 20% of those screened as eligible who did not proceed to enter the trial.
Of those entered into the trial, 41 (13%) either withdrew from the trial (n = 35) or died (n = 6) between
the start of the baseline period and the end of the follow-up period. In addition, a further two participants
died after their follow-up data had been collected but before the trial had been closed at the sites in which
they were being treated.
There was no significant difference in the rates of withdrawal between the two arms of the trial. Between the
start of baseline recording and the end of the follow-up period, 24 participants (13%) (including four who
had died) withdrew from sites at which the competency framework was being trialled and 17 participants
(13%) (including two who had died) withdrew from sites at which TAU was being delivered. Excluding death,
withdrawals occurred for one of three reasons. The most frequent reason was the failure of the research
team to be able to make contact with the participant or their informant (23 cases), with withdrawal being at
the request of the family member or paid carer acting as the informant in nine cases and at the request of
the participant in three cases.
TABLE 2 Recruitment into the trial at each site
Site Number of participants
1 28
2 24
3 10
4 16
5 22
6 20
7 20
8 20
9 23
10 17
11 10
12 18
13 5
14 34
15 17
16 12
17 16
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The numbers of missing data sets for the baseline and outcome measures are reported in Appendix 5.
These numbers include data missing both as a result of a participant being withdrawn and as a result of
that particular outcome measure not being completed. The data presented in the results tables include the
number of relevant data sets included in each instance.
Characteristics of the clinical teams taking part in the trial
The relevant staff skill mix and working practices of the contributing community teams were assessed
using the CIDT epilepsy service availability questionnaire (see Appendix 6). These data are reported in
Box 2. In addition, to help provide an indication of how representative the services participating in the trial
were of the wider population of CIDTs, Box 2 also provides comparative data from a previous survey of
53 CIDTs that took place 3 years before the EpAID trial commenced (four of the CIDTs who contributed to
the first survey also took part in the EpAID trial) (unpublished data held by Dr Howard Ring). There were a
range of differences between the teams in which the EpAID trial took place, in terms of both the way that
the teams delivered epilepsy management and the staff and resources that they had access to to do this.
However, these variations generally resembled the variations observed in the earlier survey, suggesting
that the services hosting the EpAID trial were relatively representative of CIDTs in the UK more generally.
The range of differences in the CIDT teams engaged in the EpAID trial reflects the impression gained by
members of the research team when visiting the research sites that the way in which epilepsy treatment
was delivered by CIDTs varied between teams.
BOX 2 Characteristics of the CIDTs in which the EpAID trial took placea
Location of teams
England (n = 13), Scotland (n = 2) and Wales (n = 2).
England (n = 47), Scotland, (n = 2), Wales (n = 1), Northern Ireland (n = 1), Channel Islands (n = 1) and the
Republic of Ireland (n = 1).
How many patients in total are looked after by the service?
16 responses (94%); mean = 925, median = 638, range = 120–3500.
38 responses (72%); mean = 3437.79 (with one outlier reporting a total catchment population of 110,000),
median = 400, range = 60–110,000.
How many adults looked after by the service have a diagnosis of epilepsy?
8 responses (47%); mean = 299, median = 207, range = 50–600.
34 responses (36%); mean = 123, median = 78, range = 0–550.
Does the service maintain an updated epilepsy register?
17 responses (100%); no = 12 (71%), yes = 5 (29%).
52 responses (98%); no = 45 (86.5%), yes = 7 (13.50%).
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Does the service run an epilepsy clinic?
17 responses (100%); no = 10 (59%), yes = 7 (41%).
52 responses (98%); no = 31 (60%), yes = 21 (40%).
Who delivers the epilepsy clinic?
7 responses (100% of eligible responses); ID psychiatrist+ ID nurse (n= 5), ENS (n= 1); visiting neurologist (n= 1).
15 responses (71% of eligible responses); ID psychiatrist + ID nurse (n = 4), ID psychiatrist + ENS (n = 4),
ENS (n = 2), visiting neurologist (n = 1), ID consultant (n = 2), ID consultant + neurology consultant (n = 2).
Does the community ID service include a consultant psychiatrist with a particular
interest in epilepsy?
17 responses (100%); no = 8 (47%), yes = 9 (53%).
53 responses (100%); no = 9 (17%), yes = 44 (83%).
CIDT members
15 responses (88%).
l Consultant psychiatrist:
100% of responding teams have at least one; median = 2, range = 1–7
92% of responding teams have at least one; median = 1, range = 0–8.
l Non-consultant doctors:
63% of responding teams have at least one; median number = 1.5, range = 1–6
71% of responding teams have at least one; median = 1, range = 0–8.
l Community ID/LD nurses:
94% of responding teams have at least one; median = 6, range = 0–19
86% of responding teams have at least one; median = 4, range = 0–35.
l ENSs:
44% of responding teams have at least one; median = 0, range = 0–3
21% of responding teams have at least one; median = 0, range = 0–2.
l ID/LD nurses with a special interest in epilepsy:
81% of responding teams have at least one; median = 1.5, range = 0–9
61% of responding teams have at least one; median = 1, range = 1–6.
BOX 2 Characteristics of the CIDTs in which the EpAID trial took placea (continued)
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What role(s) does the epilepsy nurse specialist/intellectual disability nurse with
a special interest in epilepsy have in epilepsy management delivered by
your service?
17 responses (100%).
46 responses (87%).
l Initial assessment of epilepsy:
undertaken in 14 (82%) services
undertaken in 30 (65%) services.
l Ongoing follow-up of epilepsy:
undertaken in 14 (82%) services
undertaken in 37 (80%) services.
l Training/care plan writing for emergency medication for prolonged seizures:
undertaken in 17 (100%) services
undertaken in 42 (91%) services.
l Telephone contact to support and advise family:
undertaken in 16 (94%) services
undertaken in 40 (87%) services.
l Visits to support and advise families:
undertaken in 16 (94%) services
undertaken in 43 (94%) services.
l Liaison with other services:
undertaken in 17 (100%) services
undertaken in 38 (83%) services.
Do intellectual disability services without an epilepsy nurse specialist have access
to epilepsy nurse specialists in other clinical services?
11 responses (100% of eligible responses); yes = 10 (91%).
52 responses (98% of eligiable responses); yes = 31 (60%).
BOX 2 Characteristics of the CIDTs in which the EpAID trial took placea (continued)
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Can the community intellectual disability service directly access relevant
investigations for epilepsy (e.g. electroencephalography, brain imaging)?
17 responses (100%); yes = 10 (59%).
51 responses (96%); yes = 45 (88%).
Does the service provide training to carers about emergency treatment of seizures?
17 responses (100%); yes = 16 (94%).
53 responses (100%); yes = 52 (98%).
Is the intellectual disability service the main provider of epilepsy management to
any of its patients?
17 responses (100%); no = 8 (47%), yes = 9 (53%).
53 responses (100%); no = 8 (15%); yes = 45 (85%).
Among those services for which this is the case, for what proportion of its
patients is it the main provider of their epilepsy management?
12 responses; mean = 45%, range = 0–98%.
41 responses; mean = 74%, range = 5–100%.
Is a local neurology service the main provider of epilepsy management to any of
the community intellectual disability team’s patients?
16 responses (94%); no = 1 (6%), yes = 15 (94%).
52 responses: no = 11 (21%); yes = 41 (79%).
Among those intellectual disability services for which this is the case, for what
proportion of its patients is a local neurology service the main provider of their
epilepsy management?
14 responses; mean = 43%, range = 2–100%.
33 responses; mean = 23%; range = 1–100%.
For those services referring patients to a local neurology service for their epilepsy
management, what referral criteria are employed?
15 responses; referral of all patients – in 2 (13%) services providing an answer, referral of those with the most
difficult to treat epilepsy – in 10 (67%) services providing an answer.
39 responses; referral of all patients – in 7 (18%) services providing an answer, referral of those with the most
difficult to treat epilepsy – in 28 (68%) services providing an answer.
BOX 2 Characteristics of the CIDTs in which the EpAID trial took placea (continued)
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Is there a joint management approach between the community intellectual
disability service and a local neurology service for any patients?
16 responses (94%); no = 7 (44%), yes = 9 (56%).
52 responses (98%); no = 27 (52%), yes = 25 (48%).
If so, for what proportion of community intellectual disability patients with
epilepsy is this the case?
11 responses; mean = 12%, range = 0–40%.
23 responses; mean = 18%, range = 1–1000%.
Does the community intellectual disability service have a role in diagnosing new
cases of epilepsy?
16 responses (94%); no = 6 (37.5%), yes = 10 (62.5%).
40 responses (76%); no = 6 (15%), yes = 34 (85%).
Does the community intellectual disability service liaise with other organisations
for the epilepsy management of its patients?
17 responses (100%); 14 services (82%) do liaise with other organisations.
35 responses (66%); 30 services (86%) do liaise with other organisations.
Does the community intellectual disability service follow an epilepsy care
pathway that makes explicit reference to people with intellectual disability?
17 responses (100%); yes = 9 (53%).
41 responses (78%); yes = 16 (39%).
In 2 services (22% of services with an epilepsy care plan) it is used just for the ongoing management
of epilepsy.
In 4 services (25% of services with an epilepsy care plan) it is used just for the ongoing management of epilepsy.
In 7 services (78% of services with an epilepsy care plan) it is used for both the diagnosis and the management
of epilepsy.
In 12 services (75% of services with an epilepsy care plan) it is used for both the diagnosis and the
management of epilepsy.
In 7 services (78%) the epilepsy care pathway was designed by the ID service itself.
In 10 services (63%) the epilepsy care pathway was designed by the ID service itself.
BOX 2 Characteristics of the CIDTs in which the EpAID trial took placea (continued)
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As described in Chapter 2 (see The intervention), the nurses delivering the intervention were allocated to
one of three levels of competence in terms of their experience at managing epilepsy in adults with an ID.
The ratings of these levels of competence are reported in Table 3. It should be noted that, although only
2% of the nurses delivering the intervention in the TAU arm were nurse prescribers, 29% of the nurses
(corresponding to five nurses) in the competency framework arm were nurse prescribers. It should also be
noted that there were more than twice the number of nurses involved in delivering treatment in the TAU
arm than there were in the competency framework arm.
Are there currently any plans to change or restructure the epilepsy management
offered by the community intellectual disability service?
17 responses (100%); yes = 4 (23.5% of services).
51 responses (96%); yes = 32 (63% of services).
a Comparative data from a previous survey of 53 CIDTs are shown in green. This first survey took place 3 years
before the EpAID trial commenced. Four of the CIDTs that contributed to the first survey also took part in the
EpAID trial.
BOX 2 Characteristics of the CIDTs in which the EpAID trial took placea (continued)
TABLE 3 Nurse competence level and banding by treatment arm
Variable
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Competence level
Novice 0/18 0.0 8/50 16.0 8/68 11.8
Competent 11/18 61.1 32/50 64.0 43/68 63.2
Expert 7/18 38.9 10/50 20.0 17/68 25.0
Prescriber
No 12/17 70.6 44/45 97.8 56/62 90.3
Yes 5/17 29.4 1/45 2.2 6/62 9.7
Full-/part-time
Full-time 8/14 57.1 17/24 70.8 25/38 65.8
Part-time 6/14 42.9 7/24 29.2 13/38 34.2
Nurse salary band
Band 5 2/15 13.3 11/46 23.9 13/61 21.3
Band 6 7/15 46.7 23/46 50.0 30/61 49.2
Band 7 3/15 20.0 11/46 23.9 14/61 23.0
Band 8a 3/15 20.0 0/46 0.0 3/61 4.9
Band 8b 0/15 0.0 1/46 2.2 1/61 1.6
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Baseline clinical characteristics of the participants
The baseline clinical and demographic characteristics of the participants are reported in Table 4.
The characteristics of the participants’ epilepsy at baseline are described in Tables 5 and 6.
TABLE 4 Description of the participants at baseline by treatment arm
Variable
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Age (years) 177 Mean 39.6 (SD 13.3);
minimum, maximum
18.1, 65.5
126 Mean 37.01 (SD 12.5);
minimum, maximum
18.4, 63.5
Sex
Male 99/184 53.8 61/128 47.7 160/312 51
Female 85/184 46.2 67/128 52.3 152/312 48.7
Ethnicity
Asian 8/179 4.5 10/125 8.0 18/304 5.9
Black 4/179 2.2 6/125 4.8 10/304 3.3
White 164/179 91.6 100/125 80.0 264/304 86.8
Mixed 2/179 1.1 3/125 2.4 5/304 1.6
Level of ID
Mild 19/173 11.0 21/107 19.6 40/280 14.3
Moderate 31/173 17.9 24/107 22.4 55/280 19.6
Severe 101/173 58.4 53/107 49.5 154/280 55.0
Profound 22/173 12.7 9/107 8.4 31/280 11.1
Accommodation arrangements
In a group home 78/177 44.1 40/122 32.8 118/299 39.5
With family members 57/177 32.2 57/122 46.7 114/299 38.1
Independently 13/177 7.3 9/122 7.4 22/299 7.4
Other 29/177 16.4 16/122 13.1 45/299 15.1
Deprivation indexa
Most deprived (0–20%) 33/179 18.4 27/126 21.4 60/305 19.7
Deprived (20–40%) 34/179 19.0 27/126 21.4 61/305 20.0
Middle (40–60%) 31/179 17.3 30/126 23.8 61/305 20.0
Not deprived (60–80%) 42/179 23.5 20/126 15.9 62/305 20.3
Least deprived
(80–100%)
39/179 21.8 22/126 17.5 61/305 20.0
a Deprivation index derived from the postcodes of participants’ accommodation.
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Causes of epilepsy, when known, and the seizure types experienced in the 2 years preceding entry into the
EpAID trial are described in Tables 7 and 8. The most common type of seizure experienced by participants,
occurring at similar rates in both arms of the trial, was tonic–clonic seizures.
Additional comorbid pathologies are relatively common in adults with ID and epilepsy. In Table 9 the
frequencies of a range of the more common current physical, psychiatric and behavioural comorbidities
known by CIDTs to be experienced by participants are listed. It is noted that, in general, the rates of
comorbidities were somewhat higher among the participants in the TAU arm than among those in the
competency framework arm.
The AEDs taken by the participants at baseline are described in Table 10. The same five AEDs were the
most frequently prescribed agents in both arms of the trial, albeit with the first and second most commonly
prescribed and the third and fourth most commonly prescribed agents reversed in order between the two
arms. However, in neither arm was there a change in the relative frequency of prescription of these AEDS
between baseline and follow-up.
TABLE 5 Seizure characteristics at baseline
Variable
Treatment arm
Active TAU
n Mean (SD)
Minimum,
maximum n Mean (SD)
Minimum,
maximum
Age (years) at epilepsy diagnosis 138 5.6 (7.6) 0, 43 75 7.3 (9.9) 0, 59
Age (years) at onset of recurrent seizures 144 4.8 (7.2) 0, 43 87 5.7 (9.4) 0, 59
Number of episodes of status in past 6 months 168 0.4 (2.7) 0, 32 101 1.6 (6.3) 0, 56
Number of prolonged seizures in past 6 months 154 2.5 (11.3) 0, 100 91 4.6 (16.3) 0, 100
Use of rescue medication in past 6 months 100 1.3 (3.0) 0, 18 63 6.6 (15.7) 0, 100
TABLE 6 Syndrome characteristics at baseline
Variable
Treatment arm
Active TAU
n/N % n/N %
Epilepsy syndrome identified
No 128/178 71.9 33/95 34.7
Yes 50/178 28.1 62/95 65.3
Epilepsy syndrome
Focal 15/46 32.6 15/54 27.8
Generalised 20/46 43.5 28/54 51.9
Undetermined 1/46 2.2 7/54 13.0
Special syndromes 10/46 21.7 4/54 7.4
Seizure type
Focal 11/173 6.4 7/85 8.2
Generalised 69/173 39.9 33/85 38.8
Focal and generalised 93/173 53.8 45/85 52.9
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TABLE 7 Aetiology of participants’ epilepsy
Variable
Treatment arm
Active TAU
n/N % n/N %
Genetic cause of epilepsy
Fragile X syndrome 1/171 0.6 0/109 0.0
Tuberous sclerosis 5/171 2.9 3/109 2.8
Rett syndrome 1/171 0.6 6/109 5.5
Angelman syndrome 2/171 1.2 1/109 0.9
Acquired causes of epilepsy
Birth injury 11/171 6.4 2/109 1.8
Cerebral palsy 25/171 14.6 4/109 3.7
Infantile brain injury 3/171 1.8 2/109 1.8
Brain infection 10/171 5.8 1/109 0.9
Prolonged febrile convulsion 2/171 1.2 3/109 2.8
Intracranial haemorrhage 1/171 0.6 1/109 0.9
Other causes of epilepsy 34/171 19.9 19/109 17.4
Unknown reason 76/171 44.4 67/109 61.5
Non-epileptic seizure(s) reported in the past 6 months in those known to have them
No 3/13 23.1 4/8 50.0
Yes 10/13 76.9 4/8 50.0
No knowledge of non-epileptic seizure diagnostic status 36/175 20.6 37/107 34
TABLE 8 Seizure types experienced by participants in the 2 years preceding their enrolment in the EpAID trial
Seizure type
Treatment arm
Active TAU
n/N % n/N %
Absence 56/174 32.2 26/105 24.8
Atonic 24/174 13.8 9/105 8.6
Tonic 36/174 20.7 20/105 19.0
Clonic 5/174 2.9 4/105 3.8
Tonic–clonic 153/174 87.9 86/105 81.9
Simple partial (focal) 27/174 15.5 5/104 4.8
Complex partial (focal) 80/174 46.0 32/104 30.8
Myoclonic 23/174 13.2 26/105 24.8
Drop attacks 11/174 6.3 11/105 10.5
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TABLE 9 Frequency of additional current comorbid conditions
Comorbid condition
Treatment arm
Active TAU
n/N % n/N %
Cardiovascular 13/178 7.3 5/111 4.5
Respiratory 20/178 11.2 23/111 20.7
Gastrointestinal 25/177 14.1 37/111 33.3
Genitourinary 11/178 6.2 17/111 15.3
Endocrine 4/177 2.3 12/111 10.8
Neurological 49/177 27.7 44/110 40.0
Musculoskeletal 47/178 26.4 33/110 30.0
Dermatological 13/178 7.3 16/111 14.4
Sight 22/177 12.4 32/111 28.8
Hearing 8/178 4.5 9/111 8.1
Autism 49/178 27.5 25/110 22.7
Challenging behaviour 54/178 30.3 46/111 41.4
Psychiatric 19/178 10.7 19/111 17.1
Other 14/176 8.0 31/107 29.0
TABLE 10 Antiepileptic drugs prescribed
AED
Treatment arm
Active, n TAU, n
Baseline Follow-up Change Baseline Follow-up Change
Carbamazepine 55 51 –4 35 34 –1
Clobazam 35 38 3 27 19 –8
Clonazepam 4 6 2 9 12 3
Eslicarbazepine 1 1 0 0 0 0
Ethosuximide 1 1 0 0 0 0
Gabapentin 2 1 –1 3 3 0
Lacosamide 16 19 3 10 11 1
Lamotrigine 77 71 –6 51 41 –10
Levetiracetam 68 64 –4 33 30 –3
Oxcarbazepine 4 3 –1 5 5 0
Perampanel 3 0 –3 1 1 0
Phenobarbitone 8 5 –3 3 3 0
Phenytoin 11 7 –4 14 14 0
Pregabalin 5 6 1 3 1 –2
Primidone 1 1 0 0 0 0
Rufinamide 0 2 2 3 1 –2
Sodium valproate 76 68 –8 61 54 –7
Topiramate 18 17 –1 11 11 0
Vigabatrin 2 1 –1 2 2 0
Zonisamide 7 7 0 6 4 –2
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Clinical outcomes
Baseline and follow-up end point data
The primary outcome measure employed to assess the effect of introducing the competency framework
was the ELDQoL-SSS. This is a 14-item questionnaire that measures the views of an informant as to how
severe the physical and behavioural manifestations and consequences of a participant’s seizures have
been, overall, in the preceding 4 weeks. The ELDQoL inventory also provides three further subscales that
rate carer concerns regarding AED side effects experienced by participants, participants’ behaviour and
participants’ mood. The mean values obtained from the trial participants on the ELDQoL subscales at
baseline and at the follow-up assessment are provided in Tables 11 and 12.
The average magnitude of change from baseline to follow-up on each of these subscales is summarised
in Table 13. Before controlling for cluster effects and baseline individual- and cluster-level covariates,
all average ELDQoL subscale scores in both arms of the trial reduced by small amounts from baseline
to follow-up.
The number of tonic–clonic seizures recorded by family carers or paid support workers was also collected
as end point data. Although many participants also had other seizure types, including focal or myoclonic
seizures, and a minority (see Table 8) did not have any tonic–clonic seizures, the number of tonic–clonic
seizures was selected as one of the end-point data sets as their occurrence is generally associated with
greater health risks for people with epilepsy than other seizure types and they can be more reliably
detected and counted. The numbers of tonic–clonic seizures recorded for participants during the baseline
and follow-up periods are reported in Table 14.
Modified Carer Strain Index scores were also collected from family carers, but not from paid carers, as a
measure of emotional, financial and practical stresses experienced by carers. Family carers’ scores on the
MCSI are reported in Table 15.
TABLE 11 Epilepsy and Learning Disabilities Quality of Life scale baseline scores
Variable
Treatment arm
Active TAU
n Mean (SD) Minimum, maximum n Mean (SD) Minimum, maximum
SSS 176 22.48 (9.55) 9.0, 45.0 123 23.07 (9.70) 9.0, 46.0
AED side effects scale 154 28.18 (10.76) 18.0, 62.0 117 30.73 (11.68) 18.0, 69.0
Behaviour scale 176 16.21 (6.50) 8.0, 32.0 125 17.38 (6.45) 8.0, 33.0
Mood scale 175 27.30 (8.69) 15.0, 48.0 125 29.13 (9.64) 15.0, 52.0
TABLE 12 Epilepsy and Learning Disabilities Quality of Life scale follow-up scores
Variable
Treatment arm
Active TAU
n Mean (SD) Minimum, maximum n Mean (SD) Minimum, maximum
SSS 161 21.83 (10.36) 9.0, 43.0 111 21.14 (9.98) 9.0, 45.0
AED side effects scale 147 27.48 (11.06) 18.0, 61.0 105 28.67 (10.69) 18.0, 62.0
Behaviour scale 161 15.65 (6.51) 8.0, 33.0 110 16.28 (6.77) 8.0, 33.0
Mood scale 157 26.01 (8.74) 15.0, 43.0 111 26.64 (8.81) 15.0, 46.0
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Primary outcome analysis
Using an ITT analysis and controlling for baseline individual- and cluster-level variables, as reported in
Tables 16 and 17 (which respectively report the analyses of the collected data set and the full data set with
MI), there was no significant difference in ELDQoL-SSS score between the two arms of the trial (–0.326,
95% CI –4.382 to 3.731; p = 0.875) (possible scores range from 10 to 56, with a higher score indicating
greater severity).
In determining the sample size for the trial, we chose to power it for the change between baseline and
follow-up in the ELDQoL-SSS score, assuming an ICC of 0.05. However, analysis of the scores collected in
the trial revealed an ICC of 0.139 [standard error (SE) 0.072, 95% CI 0.047 to 0.344]. Thus, the power of
the trial to detect a significant difference between the arms in ELDQoL-SSS score between baseline and
follow-up will have been smaller than that originally anticipated.
TABLE 14 Numbers of tonic–clonic seizures experienced during baseline and follow-up
Variable
Treatment arm
Active TAU
n Mean (SD) Minimum, maximum n Mean (SD) Minimum, maximum
Baseline 173 4.4 (10.5) 0, 83 118 4.3 (14.9) 0, 145
Follow-up 156 6.3 (19.9) 0, 160 100 3.2 (7.3) 0, 36
Change 153 2.0 (16.8) –29, 151 98 –0.2 (8.4) –47, 36
TABLE 15 Modified Carer Strain Index scores collected from family carers during baseline and follow-up
Variable
Treatment arm
Active TAU
n Mean (SD) Minimum, maximum n Mean (SD) Minimum, maximum
Baseline 54 13.42 (6.67) 0, 25 54 13.07 (5.89) 2, 26
Follow-up 41 13.93 (6.80) 0, 25 34 13.13 (5.09) 3, 26
Change 36 –0.37 (5.21) –13, 12 28 –1.06 (4.38) –13, 5
TABLE 13 Epilepsy and Learning Disabilities Quality of Life scale scores: changes from baseline
Variable
Treatment arm
Active TAU
n Mean (SD) Minimum, maximum n Mean (SD) Minimum, maximum
SSS 160 –0.75 (9.83) –33.0, 31.0 109 –1.21 (8.62) –30.0, 25.0
AED side effects
scale
131 –0.07 (9.16) –30.0, 28.0 100 –1.76 (11.72) –39.0, 27.0
Behaviour scale 160 –0.56 (6.29) –22.0, 19.0 109 –0.94 (5.78) –17.0, 21.0
Mood scale 156 –1.51 (8.95) –33.0, 25.0 110 –2.11 (10.48) –37.0, 23.0
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TABLE 16 Primary analysis: ELDQoL-SSS score (complete cases, n= 238)
Variable β (SE) p-value 95% CI
Treatment arm
Active Baseline
TAU –0.326 (2.070) 0.875 –4.382 to 3.731
Sex
Male Baseline
Female 0.679 (1.078) 0.529 –1.433 to 2.791
Baseline ELDQoL-SSS score –0.444 (0.062) < 0.001 –0.566 to –0.322
Baseline number of tonic–clonic seizures 0.007 (0.043) 0.872 –0.078 to 0.092
Age 0.037 (0.047) 0.433 –0.055 to 0.129
Accommodation
In a group home Baseline
With family members 2.515 (1.467) 0.086 –0.360 to 5.390
Independently 3.176 (2.207) 0.150 –1.150 to 7.502
Other 0.147 (1.700) 0.931 –3.185 to 3.478
Level of ID
Mild Baseline
Moderate 0.287 (1.924) 0.881 –3.484 to 4.058
Severe 0.075 (1.679) 0.964 –3.215 to 3.366
Profound 1.975 (2.372) 0.405 –2.673 to 6.623
Deprivation index
Most deprived (0–20%) Baseline
Deprived (20–40%) –0.915 (1.831) 0.618 –4.504 to 2.675
Middle (40–60%) –0.687 (1.833) 0.708 –4.279 to 2.905
Not deprived (60–80%) 1.078 (1.829) 0.555 –2.506 to 4.663
Least deprived (80–100%) –1.836 (1.816) 0.312 –5.394 to 1.722
Nurse competency level –0.732 (2.620) 0.780 –5.867 to 4.403
Overall nurse workload 0.039 (0.107) 0.718 –0.171 to 0.249
Constant 6.800 (6.707) 0.311 –6.345 to 19.946
SE, standard error.
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TABLE 17 Primary analysis: ELDQoL-SSS score (imputed data, n = 312)
Variable β (SE) p-value 95% CI
Treatment arm
Active Baseline
TAU –0.213 (1.959) 0.913 –4.053 to 3.626
Sex
Male Baseline
Female 0.664 (0.999) 0.507 –1.295 to 2.622
Baseline ELDQoL-SSS score –0.461 (0.058) < 0.001 –0.574 to –0.347
Baseline number of tonic–clonic seizures 0.025 (0.043) 0.552 –0.059 to 0.109
Age 0.021 (0.044) 0.629 –0.065 to 0.108
Accommodation
In a group home Baseline
With family members 1.438 (1.328) 0.279 –1.164 to 4.041
Independently 2.283 (2.100) 0.277 –1.832 to 6.399
Other 0.217 (1.580) 0.891 –2.879 to 3.313
Level of ID
Mild Baseline
Moderate 0.390 (1.859) 0.834 –3.253 to 4.033
Severe –0.276 (1.711) 0.872 –3.630 to 3.079
Profound 1.789 (2.350) 0.446 –2.817 to 6.395
Deprivation index
Most deprived (0–20%) Baseline
Deprived (20–40%) –1.587 (1.656) 0.338 –4.833 to 1.659
Middle (40–60%) –0.905 (1.696) 0.594 –4.229 to 2.420
Not deprived (60–80%) 0.916 (1.735) 0.598 –2.485 to 4.317
Least deprived (80–100%) –2.494 (1.676) 0.137 –5.779 to 0.791
Nurse competency level 0.241 (2.443) 0.922 –4.547 to 5.029
Overall nurse workload 0.052 (0.099) 0.597 –0.142 to 0.246
Constant 6.029 (6.150) 0.327 –6.025 to 18.083
SE, standard error.
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The analyses reported in Tables 16 and 17 indicate that, across the trial arms, there was a significant
effect of baseline ELDQoL-SSS score on follow-up score, with higher scores at baseline falling further at
follow-up.
Secondary outcome analysis
Analyses of the secondary outcomes, controlling for baseline individual- and cluster-level variables,
are reported in Tables 18–22, using full data sets with MI when appropriate.
TABLE 18 Secondary analysis: ELDQoL AED side effects scale score (imputed data, n= 312)
Category β (SE) p-value 95% CI
Treatment arm
Active Baseline
TAU 0.194 (1.620) 0.905 –2.981 to 3.369
Baseline ELDQoL-SSS score –0.499 (0.060) < 0.001 –0.617 to –0.382
Baseline number of tonic–clonic seizures 0.003 (0.056) 0.964 –0.107 to 0.112
Sex
Male Baseline
Female 0.509 (1.163) 0.662 –1.771 to 2.789
Age 0.035 (0.053) 0.499 –0.067 to 0.138
Accommodation
In a group home Baseline
With family members 1.900 (1.578) 0.228 –1.192 to 4.993
Independently 2.652 (2.622) 0.312 –2.488 to 7.792
Other 1.472 (1.967) 0.454 –2.384 to 5.327
Level of ID
Mild Baseline
Moderate –2.541 (2.181) 0.244 –6.815 to 1.734
Severe –1.159 (1.871) 0.536 –4.826 to 2.508
Profound –1.364 (2.846) 0.632 –6.942 to 4.214
Deprivation index
Most deprived (0–20%) Baseline
Deprived (20–40%) –1.879 (2.000) 0.348 –5.798 to 2.041
Middle (40–60%) –2.591 (1.927) 0.179 –6.368 to 1.186
Not deprived (60–80%) –1.236 (1.945) 0.525 –5.047 to 2.576
Least deprived (80–100%) –4.357 (1.961) 0.026 –8.201 to –0.514
Nurse competency level 1.646 (1.902) 0.387 –2.081 to 5.373
Overall nurse workload –0.044 (0.077) 0.564 –0.196 to 0.107
Constant 11.192 (5.464) 0.041 0.483 to 21.902
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There were no significant differences between the arms in ELDQoL AED side effects scale score (p = 0.905)
(see Table 18), ELDQoL behaviour scale score (p = 0.508) (see Table 19), ELDQoL mood scale score
(p = 0.580) (see Table 20), MCSI score (p = 0.727) (see Table 21) or number of tonic–clonic seizures
(p = 0.278) (see Table 22).
As was the case for the primary outcome, for each of these secondary outcomes there was a significant
effect of baseline level on the follow-up result, with participants who achieved more pathological scores at
baseline demonstrating more of a decrease towards less pathological scores at follow-up.
TABLE 19 Secondary analysis: ELDQoL behaviour scale score (imputed data, n= 312)
Category β (SE) p-value 95% CI
Treatment arm
Active Baseline
TAU 0.661 (0.998) 0.508 –1.295 to 2.617
Baseline ELDQoL-SSS score –0.507 (0.059) < 0.001 –0.622 to –0.391
Baseline number of tonic–clonic seizures 0.023 (0.028) 0.414 –0.032 to 0.077
Sex
Male Baseline
Female 0.023 (0.659) 0.972 –1.268 to 1.315
Age 0.017 (0.029) 0.568 –0.040 to 0.073
Accommodation
In a group home Baseline
With family members 1.160 (0.862) 0.179 –0.531 to 2.850
Independently 0.624 (1.444) 0.666 –2.206 to 3.454
Other 0.229 (1.061) 0.830 –1.852 to 2.309
Level of ID
Mild Baseline
Moderate 0.125 (1.188) 0.916 –2.454 to 2.203
Severe 1.319 (1.060) 0.213 –0.759 to 3.398
Profound 3.250 (1.575) 0.039 0.162 to 6.338
Deprivation index
Most deprived (0–20%) Baseline
Deprived (20–40%) –0.470 (1.115) 0.673 –2.655 to 1.715
Middle (40–60%) –0.772 (1.157) 0.504 –3.040 to 1.495
Not deprived (60–80%) 0.265 (1.181) 0.823 –2.050 to 2.581
Least deprived (80–100%) –1.070 (1.138) 0.347 –3.299 to 1.160
Nurse competency level 0.295 (1.232) 0.811 –2.120 to 2.709
Overall nurse workload 0.054 (0.050) 0.283 –0.045 to 0.153
Constant 3.346 (3.333) 0.315 –3.187 to 9.879
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Subgroup analyses
The planned subgroup analyses, as specified in the trial statistical analysis plan before data analysis
commenced (see Chapter 2, Clinical outcome analyses), are reported in Table 23. There was a significant
interaction between ELDQoL-SSS score and treatment arm and level of ID.
Further analysis of this interaction revealed that, for those with a mild/moderate ID (n = 95), the follow-up
SSS score minus the baseline SSS score was, on average, 3.376 higher (i.e. worse) in the TAU arm than in
the competency framework arm (a non-significant trend: SE 2.005, 95% CI –0.554 to 7.307; p = 0.092).
However, among participants with a severe/profound group ID (n = 185), the follow-up SSS score
minus the baseline SSS score was 1.968 lower in the TAU arm than in the competency framework arm
(a non-significant change: SE = 2.557, 95% CI –6.981 to 3.044; p = 0.442). However, the treatment
effect was not significant in either arm.
TABLE 20 Secondary analysis: ELDQoL mood scale score (imputed data, n= 312)
Category β (SE) p-value 95% CI
Treatment arm
Active Baseline
TAU 0.854 (1.541) 0.580 –2.167 to 3.874
Baseline ELDQoL-SSS score –0.645 (0.058) < 0.001 –0.760 to –0.531
Baseline number of tonic–clonic seizures 0.049 (0.041) 0.231 –0.031 to 0.129
Sex
Male Baseline
Female 0.425 (0.973) 0.662 –1.482 to 2.332
Age 0.012 (0.043) 0.778 –0.072 to 0.096
Accommodation
In a group home Baseline
With family members 1.968 (1.274) 0.122 –0.529 to 4.465
Independently 2.999 (2.255) 0.184 –1.421 to 7.418
Other 1.578 (1.562) 0.313 –1.485 to 4.640
Level of ID
Mild Baseline
Moderate 0.436 (1.853) 0.814 –3.195 to 4.067
Severe 0.940 (1.616) 0.561 –2.227 to 4.107
Profound 1.220 (2.337) 0.601 –3.359 to 5.800
Deprivation index
Most deprived (0–20%) Baseline
Deprived (20–40%) –1.486 (1.603) 0.354 –4.628 to 1.656
Middle (40–60%) –1.549 (1.624) 0.340 –4.732 to 1.634
Not deprived (60–80%) 1.610 (1.673) 0.336 –1.670 to 4.889
Least deprived (80–100%) –1.955 (1.631) 0.231 –5.151 to 1.242
Nurse competency level 0.281 (1.913) 0.883 –3.468 to 4.030
Overall nurse workload 0.066 (0.078) 0.399 –0.087 to 0.219
Constant 11.326 (5.382) 0.035 0.778 to 21.874
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The other planned subgroup analyses did not indicate any other significant interactions between the
primary end point and baseline variables (see Table 23).
Trial-related clinical activities carried out by the treating nurses
Using the nurse self-completion daily activity diary, as described in End points: definitions and acquisition,
data were collected on the duration and nature of all clinical work, pertaining to the participants,
undertaken by the nurses during the intervention period. The aim of collecting these data was to generate
profiles of the clinical needs addressed and the interventions given to participants in the two study arms to
provide an indication of the extent to which the competency framework altered clinical practice. Overall,
it was found that the reasons for intervention (χ2 = 54.50, degrees of freedom = 10; p < 0.001) and the
TABLE 21 Secondary analysis: MCSI score (imputed data, n = 96)
Category β (SE) p-value 95% CI
Treatment arm
Active Baseline
TAU –0.569 (1.631) 0.727 –3.766 to 2.629
Baseline ELDQoL-SSS score –0.386 (0.105) < 0.001 –0.592 to –0.180
Baseline number of tonic–clonic seizures –0.005 (0.030) 0.876 –0.064 to 0.055
Sex
Male Baseline
Female 1.148 (1.358) 0.398 –1.514 to 3.810
Age –0.022 (0.071) 0.763 –0.161 to 0.118
Accommodation
In a group home Baseline
With family members –3.084 (3.697) 0.404 –10.330 to 4.162
Independently 0.324 (4.173) 0.938 –7.855 to 8.504
Other –2.694 (4.491) 0.549 –11.496 to 6.109
Level of ID
Mild Baseline
Moderate 1.668 (2.321) 0.472 –2.882 to 6.217
Severe 0.464 (2.215) 0.834 –3.878 to 4.806
Profound 0.635 (2.711) 0.815 –4.678 to 5.949
Deprivation index
Most deprived (0–20%) Baseline
Deprived (20–40%) –0.046 (1.922) 0.981 –3.814 to 3.722
Middle (40–60%) –0.206 (2.097) 0.922 –4.316 to 3.904
Not deprived (60–80%) –0.937 (2.198) 0.670 –5.246 to 3.372
Least deprived (80–100%) –0.279 (1.985) 0.888 –4.169 to 3.610
Nurse competency level 0.041 (1.869) 0.982 –3.621 to 3.704
Overall nurse workload –0.052 (0.072) 0.472 –0.194 to 0.090
Constant 8.964 (6.093) 0.141 –2.978 to 20.906
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details of the care given (χ2 = 94.69, degrees of freedom = 10; p < 0.001) were both significantly different
between the two arms of the trial.
Table 24 demonstrates that, on average, the nurses working in the active intervention arm engaged in
fewer episodes of care with participants than those working in the TAU arm (mean difference = 1.961
fewer contacts in the active intervention arm, SE 0.586, 95% CI –3.644 to –0.277; p = 0.023). Although
within each arm there was a wide variation in the duration of individual contacts, the clinical contacts in
both arms had a similar average duration of around 40 minutes.
Tables 25–27 provide, respectively, details of the location of each episode of care, the reason or reasons
for it and the nature of the care provided or intervention delivered.
TABLE 22 Secondary analysis: number of tonic–clonic seizures (imputed data, n= 312)
Category β (SE) p-value 95% CI
Treatment arm
Active Baseline
TAU –3.143 (2.898) 0.278 –8.823 to 2.537
Baseline number of tonic–clonic seizures –0.405 (0.140) 0.004 –0.680 to –0.130
Sex
Male Baseline
Female 0.025 (1.669) 0.988 –3.246 to 3.296
Age –0.034 (0.071) 0.635 –0.173 to 0.105
Accommodation
In a group home Baseline
With family members 2.761 (2.123) 0.193 –1.400 to 6.923
Independently 1.199 (3.444) 0.728 –5.551 to 7.948
Other 3.566 (2.739) 0.193 –1.802 to 8.934
Level of ID
Mild Baseline
Moderate 0.046 (2.977) 0.988 –5.789 to 5.880
Severe 1.410 (2.580) 0.585 –3.647 to 6.467
Profound –0.314 (3.812) 0.934 –7.786 to 7.158
Deprivation index
Most deprived (0–20%) Baseline
Deprived (20–40%) –4.072 (2.695) 0.131 –9.354 to 1.210
Middle (40–60%) –3.147 (2.770) 0.256 –8.577 to 2.284
Not deprived (60–80%) –3.122 (2.953) 0.290 –8.909 to 2.665
Least deprived (80–100%) –4.659 (2.894) 0.107 –10.331 to 1.014
Nurse competency level 2.384 (3.543) 0.501 –4.560 to 9.328
Overall nurse workload –0.131 (0.144) 0.362 –0.413 to 0.151
Constant 3.471 (8.877) 0.696 –13.927 to 20.869
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TABLE 23 Planned subgroup analyses of interactions between treatment arm and variables describing baseline
seizure severity, level of ID and accommodation with respect to seizure severity outcome, and between treatment
arm and baseline number of tonic–clonic seizures with respect to MCSI score
Outcome Variable Category n β (SE) p-value 95% CI
Change in
ELDQoL-SSS
score
Baseline number of
tonic–clonic seizures
312 –0.055 (0.084) 0.513 –0.221 to 0.110
Change in
ELDQoL-SSS
score
Baseline SSS Below median 312 Baseline
Above median 1.932 (1.915) 0.313 –1.820 to 5.684
Change in
ELDQoL-SSS
score
Level of ID Mild/moderate 312 Baseline
Severe/profound –5.280 (2.229) 0.018 –9.649 to –0.910
Change in
ELDQoL-SSS
score
Accommodation In a group home 312 Baseline
With family 1.581 (2.522) 0.531 –3.361 to 6.524
Independently 1.036 (4.363) 0.812 –7.515 to 9.586
Other 3.737 (3.289) 0.256 –2.711 to 10.184
Change in
ELDQoL-SSS
score
Baseline number of
seizure types
0/1 seizure types 279 Baseline
> 1 seizure type 0.900 (1.884) 0.633 –2.793 to 4.593
Change in
MCSI score
Baseline number of
tonic–clonic seizures
96 –0.022 (0.067) 0.738 –0.154 to 0.109
TABLE 24 Trial-related episodes of care by the nurses delivering treatment
Variable
Treatment arm
Active TAU
n Median Minimum, maximum n Median Minimum, maximum
Number of contactsa 184 2 0, 36 128 5 0, 40
Duration of contact (minutes) 900 30 0, 603 890 30 0, 420
a Mean difference = 1.961 fewer contacts in the active intervention arm (SE 0.586, 95% CI –3.644 to –0.277; p= 0.023).
TABLE 25 Location of episode of care
Location
Treatment arm
Active TAU
n/N % n/N %
Home 292/940 31.1 336/904 37.2
Clinic 105/940 11.2 72/904 8.0
GP surgery 6/940 0.6 9/904 1.0
Telephone 200/940 21.3 285/904 31.5
Other 337/940 35.9 202/904 22.3
There were three occasions in each group when a contact took place but no information was provided as to the location of
that contact. The denominator used in this table is the number of contacts in which a location was specified.
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Nurses could make use of as many of the available responses as they considered appropriate to describe
the reasons for and nature of each episode of care. Examination of these tables and Figures 4 and 5
provides an impression of the activities that the treating nurses in the two arms engaged in and why.
In addition, planned comparisons were carried out to examine a priori hypotheses that the nature of the
competency framework guidelines would result in a higher proportion of contacts for health facilitation and
a lower proportion of contacts in response to urgent health or behavioural concerns in the competency
framework arm. As reported in Table 26, there was no significant difference between the arms with respect
to the proportion of contacts for health facilitation, whereas, against expectations, the proportion of
contacts relating to urgent health or behavioural concerns was greater in the active arm.
TABLE 26 Reason(s) for episodes of care
Reasona
Treatment arm
Active TAU
n/N % n/N %
Assessment 48/943 5.1 93/907 10.3
Counselling 10/943 1.1 11/907 1.2
Education 43/943 4.6 51/907 5.6
Health facilitation 188/943 19.9 155/907 17.1
Management planning 159/943 16.9 173/907 19.1
Monitoring epilepsy 444/943 47.1 445/907 49.1
Monitoring health/behaviour 243/943 25.8 321/907 35.4
Monitoring treatment 278/943 29.5 240/907 26.5
Responding to urgent health or behavioural concern 116/943 12.3 81/907 8.9
Other 163/943 17.3 129/907 14.2
a Overall, reasons for episodes of care differed between trial arms (χ2 = 54.50, degrees of freedom = 10; p< 0.001).
TABLE 27 Intervention(s) delivered
Interventiona
Treatment arm
Active TAU
n/N % n/N %
Education of family carer 39/943 4.1 61/907 6.7
Education of paid staff 131/943 13.9 111/907 12.2
Education of patient 25/943 2.7 50/907 5.5
Health facilitation 273/943 29.0 284/907 31.3
Investigation request 39/943 4.1 53/907 5.8
Management planning 288/943 30.5 302/907 33.3
Medication issues 206/943 21.8 140/907 15.4
Prescribing 76/943 8.1 21/907 2.3
Review and monitoring of medication 319/943 33.8 206/907 22.7
Other 255/943 27.0 262/907 28.9
a Overall, the nature of the intervention delivered was significantly different between the two arms of the trial (χ2 = 94.69,
degrees of freedom = 10; p< 0.001).
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FIGURE 4 Reasons for each intervention as a proportion of all reasons cited for an intervention.
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FIGURE 5 Care delivered during an intervention as a proportion of all interventions delivered.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
48
Safety findings
The frequency and proportions of serious adverse events (SAEs), including deaths, that occurred during the
trial in the two arms are reported in Table 28, summarised as the consequence of the SAE, the view of the
local principal investigator (PI) as to whether or not the SAE was likely to have been caused by participation
in the EpAID trial and the outcome of the event. Overall, there was no significant difference between
the two arms of the trial in the proportion of participants who experienced a SAE. The proportion of
participants in the competency framework arm who experienced a SAE was 0.136 and in the TAU arm
was 0.094 (estimated difference 0.042, 95% CI –0.029 to 0.113; p = 0.258).
A full list of the SAEs reported is provided in Appendix 3.
Of the 184 participants entered into the active arm of the trial, four died at some point between being
consented into the trial and completing the period of follow-up observation. Of the 128 participants
randomised to the TAU arm, two people died over the same period. Of these six deaths, five were attributed
to respiratory pathology and one to cardiac disease. None were directly associated with epilepsy and in no
instance did the local PI consider that the death was associated with participation in the EpAID trial.
Economic analyses: results
Raw resource use and outcome data
All 312 participants included in the primary statistical analysis were included in the economic analysis.
Table 29 provides mean values and the proportion of missing data for cost and outcome data at baseline
and follow-up in the intervention and control arms. The number of missing data for costs was small at
baseline and modest at follow-up. The number of missing data for outcomes was greater, but in all cases
at least 70% of data were non-missing. Over half of the costs falling on health and social care were
accommodation costs. Social care and day care costs were also high. The costs falling on participants/
families for the provision of respite care, holidays, social care and transport constitute a modest share of
the total monthly costs, but at around £200 per month may represent a significant burden. Informal care
costs were much higher and constituted the main difference between costs falling on health and social
care and societal costs. Drug costs were generally low but included some high-cost items such as rescue
TABLE 28 Serious adverse events
Variable
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Consequences
Death 4/184 2.2 2/128 1.6 8/312 2.6
Hospitalisation 30/184 16.3 20/128 15.6 50/312 16.0
Other 3/184 1.6 0/128 0.0 3/312 1.0
Caused by participation in the EpAID trial
No 33/184 17.9 21/128 16.4 54/312 17.3
Yes 0/184 0.0 1/128 0.8 1/312 0.3
Outcome
Resolved 17/184 9.2 12/128 9.4 29/312 9.3
Ongoing 6/184 3.3 2/128 1.6 8/312 2.6
Death 6/184 3.3 2/128 1.6 8/312 2.6
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medication and fortified drinks. The costs of holidays, hospitalisations and contact with the treating nurse
were low. There was a sizeable increase in accommodation costs in the control arm at follow-up compared
with baseline, which was not replicated in the intervention arm.
Figure 6 illustrates the changes in overall mean costs (after excluding missing data) by category between
baseline and follow-up. The largest absolute change was seen for accommodation costs and the largest
relative change was seen for hospital costs. However, the data for hospital costs along with holiday costs
contained a large number of zero observations, increasing sensitivity to outliers.
The distribution of overall health and social care costs was moderately skewed. Figure 7 shows the
distribution for all patients at follow-up. After removing accommodation costs, the distribution of the
remaining costs exhibited greater skew. Using generalised linear modelling, alternative distributions and
link functions were examined to see if they would provide a better fit with the data than the assumption
TABLE 29 Raw cost and outcome data at baseline and follow-up by treatment group
Variable
Treatment arm
Active (n= 184) TAU (n= 128)
Baseline Follow-up Baseline Follow-up
Mean
Proportion
missing (%) Mean
Proportion
missing (%) Mean
Proportion
missing (%) Mean
Proportion
missing (%)
Costs by category (£)
Drugs 160 0 174 0 200 0 160 0
Accommodation 3853 4 3938 14 2949 5 3351 17
Respite care 176 4 153 14 129 5 165 19
Holidays 71 4 54 14 70 5 70 19
Primary health 181 4 162 14 221 5 244 19
Social care 795 4 559 14 859 5 775 19
Day care 996 4 1062 14 980 5 1259 19
Hospital visits 25 4 54 14 50 5 93 19
Patient costs 208 0 224 0 156 0 165 0
Informal care 1745 4 1783 14 2537 4 2652 19
Treating nurse NA 63 0 NA 58 0
Total health and
social care
6276 4 6253 14 5470 5 6288 19
Total societal 8237 4 8295 14 8191 5 9142 20
Outcomes
EQ-5D-5L tariff 0.63 17 0.60 22 0.62 16 0.62 28
EQ-5D-5L VAS 76 5 76 14 74 7 77 20
ELDQoL-SSS 26.6 16 27.0 21 26.1 13 25.6 23
ELDQoL mood 31.2 5 30.9 15 31.6 2 30.9 13
ELDQoL
behaviour
18.5 5 18.5 13 18.8 2 18.5 14
ELDQoL AED SEP 31.3 20 31.1 25 32.5 9 31.9 20
NA, not applicable; SEP, side effects profile; VAS, visual analogue scale.
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of normally distributed residuals underpinning linear regression. However, tests of the variance and link
functions did not reliably identify superior alternatives to linear regression. The distribution of EQ-5D-5L
tariffs was also moderately skewed. Figure 8 shows the distribution of EQ-5D-5L tariff values at follow-up.
Table 30 reports the mean treatment effects and the non-parametric 95% CIs derived following MI of
missing data and adjustment for differences at baseline using linear regression.
The data suggest that the intervention is associated with a reduction in monthly costs compared with
TAU. The data also indicate that the treatment is associated with a reduction in QoL. In all cases the
effect associated with treatment is not significant at the 95% confidence level. The data suggest that the
competency framework might reduce the cost of supporting people with epilepsy and an ID but provide
worse outcomes than usual care.
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Table 30 reports differences in costs over the previous month at follow-up between the treatment group
and the control group after adjusting for baseline differences. Assumptions are required regarding the
impact of treatment on costs in the intervening 5 months. Likewise, the EQ-5D-5L captures patients’ health
status on the day that the questionnaire is completed and assumptions are needed regarding QoL measures
between baseline and follow-up. The most common assumption is a linear interpolation between baseline
and follow-up. With respect to the ICER, this is mathematically equivalent to assuming an immediate
change in QoL and costs following commencement of the intervention (the proportionate effect on the
numerator and the denominator is the same). Using Equation 1 for the ICER (see Economic analysis), either
assumption generates ICERs of £220,000 per QALY from a health and social care perspective and £376,000
per QALY from a societal perspective. Usual care is more effective but far more expensive and, hence, is not
cost-effective. Interpreted a little differently, the intervention results in a reduction in QoL but generates
considerable cost savings, which would justify its introduction at currently accepted thresholds. An increase
in ELDQoL-SSS score represents a worsening of severity. The ICERs for a point reduction in SSS score are
£8600 and £14,700 from a health and social care and a societal perspective respectively. It should be noted
at this point that, although it is not incorrect to interpret the mean ICERs generated from the bootstrap
replicates, the considerable uncertainty surrounding the results requires explicit consideration.
Uncertainty and correlation between costs and outcomes
The cost-effectiveness plane derived from the difference in health and social care costs and QoL estimated
using EQ-5D-5L tariff values is plotted in Figure 9. In the cost-effectiveness plane, each pair of cost and
QoL treatment effect estimates from the 1000 bootstrap replicates are plotted. The majority of points lie in
the south-west quadrant representing a reduction in both costs and QoL associated with treatment. Any
correlation between costs and outcomes appears to be small. This reflects the underlying data in which
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FIGURE 8 Distribution of EQ-5D-5L tariff values at follow-up.
TABLE 30 Treatment effects on costs and outcomes
Costs and outcomes Mean p-value 95% CI
Total annual health and social care costs (£) –358 0.36 –1119 to 294
Total annual societal costs (£) –612 0.19 –1523 to 299
QoL: EQ-5D-5L tariff –0.020 0.45 –0.071 to 0.032
QoL: ELDQoL-SSS –0.50 0.66 –2.76 to 1.76
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only a modest correlation between changes in costs and changes in EQ-5D-5L tariffs at the patient level
was observed (r = 0.12).
The pairs of treatment costs and effects from the bootstrap replicates plotted in the cost-effectiveness
plane can also be used to generate the CEAC. The resulting plot is shown in Figure 10. The CEAC
suggests that there is a roughly 85% likelihood, given sampling uncertainty, that the intervention is
cost-effective across a range of values placed on a QALY from £0 to £50,000.
The intervention is less effective than the control, and so, as the value placed on a QALY increases, the
likelihood that the intervention is cost-effective falls – but not by much because the differential impact
on QoL is small compared with costs. Over the range £0–50,000 the likelihood that the intervention is
cost-effective falls from 87% to 80%. The inference is the same as that derived from the mean ICER –
the defined epilepsy nurse role is cost-effective. However, the CEAC conveys the uncertainty around that
conclusion, which is considerable.
When societal costs are included, the treatment effect on costs tends to more negative values. This is best
seen in the corresponding cost-effectiveness plane (Figure 11).
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FIGURE 9 Cost-effectiveness plane plotted using health and social care costs and QoL measured with the EQ-5D-5L.
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FIGURE 10 Cost-effectiveness acceptability curve plotted using health and social care costs and QoL measured with
the EQ-5D-5L.
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Comparing this figure with the cost-effectiveness plane for health and social care costs (see Figure 9) it can
be seen that the cloud of cost and effect pairs is shifted to the left. The effect appears to be modest but it
is sufficient to influence the resulting CEAC (Figure 12).
Again, the threshold value placed on a QALY has a very modest impact on uncertainty. Now, however,
the likelihood that the intervention is cost-effective increases to a little over 90%. This reflects additional
cost savings attributable to the intervention that are not included in the health and social care perspective
(costs falling on patients/families and the cost of informal care).
To generate a CEAC for the primary clinical outcome measure, a range of values capturing the threshold
value that a decision-maker might place on the outcome (a unit reduction in SSS score) needs to be
specified. The score range for the SSS score is 10–56. We chose a range of values from £0 to £2000 per
point. At the maximum value of £2000, movement from the worst possible to the best possible SSS score
would be valued at £90,000. The resulting CEACs from the health and social care (Figure 13) and societal
(Figure 14) perspectives are very similar to those generated when QoL is assessed using EQ-5D-5L tariffs
(utility). Again, the treatment protocol appears to be cost-effective.
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FIGURE 11 Cost-effectiveness plane plotted using societal costs and QoL measured with the EQ-5D-5L.
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FIGURE 12 Cost-effectiveness acceptability curve plotted using societal costs and QoL measured with the EQ-5D-5L.
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Sensitivity analysis
Subgroup analysis according to intellectual disability
The impact of the extent of ID was investigated in subgroup analysis. The resulting CEACs for the mild/
moderate and severe/profound subgroups are shown in Figures 15–18. In the mild/moderate group there is
considerable uncertainty regarding the cost-effectiveness of the intervention when the outcome measure is
the EQ-5D-5L score, which increases as the threshold value placed on a QALY is increased (see Figures 15
and 16). Indeed, at £50,000 there is a < 50% chance that the intervention is cost-effective. In contrast, for
those with severe/profound ID there is a greater chance that the intervention is cost-effective and the value
placed on outcomes has no influence on cost-effectiveness at all. These results are consistent with the
intervention effects, as measured by changes in QoL on the EQ-5D-5L, being concentrated among patients
with mild or moderate ID. The impact of the intervention on costs is more consistent across ID subgroups
but is more likely to be cost saving in patients with severe or profound ID.
A slightly different picture emerges when the outcome measure is the SSS score. Here, the intervention
has a modestly positive impact in patients with mild or moderate ID. This is evident in the CEAC (see
Figure 17), which rises as the value placed on a point improvement in the SSS score increases. This is
paired with a smaller chance of cost savings in this subgroup compared with those with severe/profound
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FIGURE 13 Cost-effectiveness acceptability curve plotted using health and social care costs and SSS scores.
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FIGURE 14 Cost-effectiveness acceptability curve plotted using societal costs and SSS scores.
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FIGURE 15 Cost-effectiveness acceptability curve plotted using health and social care costs and QoL measured with
the EQ-5D-5L for patients with mild/moderate ID.
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FIGURE 16 Cost-effectiveness acceptability curve plotted using health and social care costs and QoL measured with
the EQ-5D-5L for patients with severe/profound ID.
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FIGURE 17 Cost-effectiveness acceptability curve plotted using health and social care costs and QoL measured with
the ELDQoL-SSS for patients with mild/moderate ID.
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ID so that, across the range of values examined, the cost-effectiveness increases from 68% to 88%.
For patients with severe/profound ID the impact of the intervention on SSS score is negative. In the
absence of consideration of outcome (threshold value of £0) the intervention has an 84% chance of being
cost-effective in this group (see Figure 18). However, as the value placed on a unit improvement in SSS
score increases, the likelihood of cost-effectiveness falls, to around 70% at a threshold value of £2000 per
unit gain in SSS score.
Exclusion of accommodation costs
The impact of excluding accommodation costs is to increase the likelihood that the intervention is
cost-effective (Figure 19). This is somewhat counterintuitive when one considers the raw trial data, which
indicate a much larger rise in accommodation costs in the control arm from baseline to follow-up than in
the intervention arm. The overall cost savings from the intervention will be smaller in the absence of those
accruing from changes in accommodation. However, accommodation costs for those in the formal care
sector are high and are likely to dwarf other costs. Excluding these costs may reduce the overall variability
in the treatment effect on costs, with the result that a higher proportion of bootstrap replications generate
cost savings for the intervention arm, albeit of more modest size.
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FIGURE 18 Cost-effectiveness acceptability curve plotted using health and social care costs and QoL measured with
the ELDQoL-SSS for patients with severe/profound ID.
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FIGURE 19 Cost-effectiveness acceptability curve plotted using health and social care costs, excluding
accommodation costs, and QoL measured with EQ-5D-5L.
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Application of two-stage bootstrapping
When the data were first imputed and then bootstrapped using a two-stage bootstrap routine, the
treatment effect on monthly health and social care costs and on EQ-5D-5L tariff values was –£646 and
–0.029 respectively. Applying the previously stated assumptions regarding the interpolation of costs and
outcomes between baseline and follow-up results in an ICER for usual care of £264,000 per QALY.
Preferences of carers
The responses of participants’ primary carers when asked to value the care that the participants had
received are reported in Table 31. Of the 129 participants with a friend or relative as a primary carer, we
received a questionnaire response from 75 (58%). Table 31 reports the proportion of respondents who
perceived either an improvement or a worsening of care at follow-up compared with baseline. The vast
majority of respondents did not report any change in the quality of care, with no difference between the
intervention arm and the control arm. Carers who perceived a change in care were asked to value the care
that they perceived as superior. Nine of the 13 carers stated a maximum monthly payment that they would
be prepared to pay for their preferred level of support. Values ranged from £5 to £1000. No further
analysis of these data was undertaken.
Qualitative outcomes
The interviewees consisted of 11 family carers, of whom six were in the active arm; eight nurses, of whom
four were in the active arm; and 10 paid support workers, of whom six were in the active arm.
Interviews with family carers
Family carers’ experiences of epilepsy nurses varied considerably. In part, this was because of differences in
the severity and frequency of the seizures affecting their children, but also because their adult children
received care and treatment from nurses with various levels of training and expertise. Some patients saw
nurse prescribers, whereas other patients’ epilepsy was managed by a psychiatrist or a neurologist and
they saw nurses with little in the way of specialist epilepsy training. Family carers in this latter group
described nurses who had little direct involvement in epilepsy management, although these nurses might
visit them at home and respond to other concerns about the health and/or social care of their son or
daughter. Irrespective of the qualifications of the nurse (and the trial arm in which participants had been
treated), what these family carers appreciated was a nurse who was approachable and who could be
contacted quickly when there was a problem. Moreover, family carers particularly valued nurses who they
saw as being able to communicate effectively with other health and social care professionals, especially
with respect to writing care plans, providing or arranging epilepsy training for paid support staff and
securing social care funding for specialist equipment. All of the family carers who we interviewed were
appreciative of the nursing service that they were receiving but it was the personal characteristics and
manner of the nurses that were valued rather than their level of training and expertise in epilepsy. That
said, family carers did expect nurses to be aware of the side effects of AEDs and how these might impede
opportunities for social inclusion, as well as the impact of comorbid physical health problems. Nonetheless,
it was also apparent that, apart from the personal qualities of the nurses, these family carers were
generally poorly equipped to evaluate the service received by their son or daughter – they were largely
TABLE 31 Friends’/relatives’ views on changes to treatment during the intervention
Treatment arm
Judgement on support over the last 6 months
Improved No change Worsened
Framework 4 40 3
TAU 3 22 3
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unaware of the possibility that epilepsy management could be differently organised. They were also unable
to comment on the effectiveness of the care and treatment received, except to note that their son or
daughter’s medication had not been changed for some time.
Interviews with nurses
Interestingly, nurses in both arms struggled to recall any ‘training’ that they had received as part of their
participation in the EpAID trial. Whether in the competency framework or the TAU arm, the nurses who
we interviewed were alert to the fact that epilepsy management was complicated by the treatment of
physical illnesses; they were sensitive to the potential side effects of AEDs and the impact that this could
have on people’s lives. All respondents were aware of their duties under the Mental Capacity Act 200574
(England and Wales) to involve patients in decisions about their care and treatment, even if they lacked the
capacity to make treatment decisions. Whether a patient was supported by family members or by paid
support workers, all of the nurses who we spoke to were aware of the important role that these carers
played in managing and reporting seizure activity. All of the nurses described working in multidisciplinary
clinical teams and saw this as beneficial. A minority of the nurses did report, however, that there was less
integration with social care than there had been in the past.
Paid support staff
Like family carers, the paid support staff who we spoke to had different experiences of nursing
involvement in the care and treatment of a person’s epilepsy, which related to the different levels of
professional expertise of the nurses and differences in the arrangements of the services in which they
worked. Nonetheless, all of the paid support staff spoke highly of the nurses who they saw and again this
was related to the personal qualities of the nurses, in particular their ability to communicate and share
information. As with the family carers, paid support workers reported that the nurses who they saw were
alert to the side effects of medications, appreciated the significance of comorbid physical health problems
and understood that epilepsy and the medication used to treat it could affect opportunities for social inclusion.
Overall conclusions from the qualitative interviews
There was nothing in the interview data to suggest that there were any clearly recognisable differences
between the two arms of the study. In both arms it appeared to be the personal characteristics and
manner of the nurses that were important in determining how family carers and paid support workers felt
about the nursing input received by the participants. It was observed that services in which the nurses
worked, and in which participants – supported by their family or paid workers – accessed epilepsy care and
treatment, varied significantly, both within and between treatment arms. Although we did not specifically
ask respondents about how epilepsy services were organised, their accounts nevertheless revealed
considerable differences: epilepsy treatments were accessed through psychiatrics, neurologists or nurse
prescribers; services had different set-ups with respect to the holding of regular clinics and the making of
home visits; there were variations in the degree to which nurses saw patients themselves or referred them
on to other clinicians; and there were variations in how health services related to members of social care
teams. However, there was no evidence that how these different aspects of service delivery were perceived
by the respondents was particularly determined by which arm of the trial they were associated with.
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Chapter 4 Discussion
The intended goals of the EpAID trial
Anecdotal evidence and data from open studies have suggested that epilepsy nurse-led management
may improve some clinical outcomes and reduce treatment costs in adults with epilepsy and ID.12,13,15–21,30
However, a recently updated Cochrane review of non-pharmacological management of epilepsy76 did not
identify any RCTs of nurse-led interventions for epilepsy and indeed found only one study, of a neurosurgical
intervention, that met the requirements for inclusion in the whole review. Against this background, the aim
of the EpAID trial was to test the hypothesis that a nurse-led intervention, the Learning Disability Epilepsy
Specialist Nurse Competency Framework, would lead to cost-effective reductions in seizure severity and
improvements in other measures of QoL for patients with ID and epilepsy and those who provide care for
them in the community compared with TAU.
Interpretation of findings from the primary and secondary end points
The primary objective of the trial was to determine whether or not the participants in the active arm of the
trial experienced a reduction in their seizure severity, as measured by the ELDQoL-SSS, compared with the
participants who had continued to receive their usual treatment. Using an ITT analysis controlling for key
baseline individual and cluster-level variables, no significant difference between the experimental arm and
the TAU arm in this measure of seizure severity was observed.
Considering the secondary end points – scores on the ELDQoL AED side effects scale, the ELDQoL behaviour
scale, the ELDQoL mood scale, the MCSI (a measure of the strains and burdens of providing care as
perceived by family carers) and the number of tonic–clonic seizures – during the follow-up compared with
the baseline observation period, again, there were no significant differences between the experimental arm
and the TAU arm.
There is thus no evidence in adults with an ID and active epilepsy, as a group, that the introduction of the
competency framework led to a reduction in overall seizure severity or to improvements in any of a range
of other consequences of epilepsy and its treatment for the participants or their family carers. The absence
of any change on the MCSI is in line with the finding that, when carers who were family members were
asked during follow-up, the great majority did not report any change in the quality of care received or the
perceived value of it. Likewise, the qualitative analysis of semistructured interviews with family carers and
paid support workers demonstrated that, although these respondents were alert to various aspects of the
perceived nature and quality of their interactions with nurses delivering treatment, their perceptions were
not shaped in line with which arm of the study they had been associated with but with the personal
qualities, as the respondents perceived them, of the nurses.
It is noted that for all ELDQoL and MCSI outcomes there was a significant effect of baseline scores on
follow-up outcomes, with higher scores at baseline being associated with greater decreases in pathological
scores at follow-up. This pattern of results is most likely to reflect simple ‘regression to the mean’. The
Hawthorne effect – a non-specific change in behaviour as a motivational response to the interest, care or
attention received through observation and assessment77 – could also have resulted in improved outcomes
over the course of the trial but is less likely to have led to those with more pathological states at baseline
gaining relatively larger benefits at follow-up. With respect to changes in SSS scores in particular, in several
of the services, entry into the team in which the trial took place may have followed a recent deterioration
in a participant’s epilepsy. It is possible that this deterioration may have been self-limiting, irrespective of
any epilepsy treatment received, for instance, if it occurred as a result of an infection that was subsequently
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treated. Although this could also have contributed to the observation that higher baseline scores were
associated with greater falls at baseline, this referral model was used in only a minority of the teams and
we do not consider that it is likely to have played a significant role.
With respect to the economic analyses, however, the results indicate that nurses asked to work in line with
the competency framework are likely to be cost-effective compared with nurses working in the TAU arm,
although there is considerable uncertainty in this finding. Thus, the use of the competency framework
appeared to result in a modest decrement in QoL assessed using the EQ-5D-5L and the SSS of the ELDQoL,
but a sizeable reduction in the costs associated with caring for participants. However, the 95% confidence
limits estimated from the bootstrap replicates include zero for both societal and health and social care
costs and both QoL measures. Likewise, the likelihood that the intervention is cost-effective is always
below 95% across the range of thresholds considered in the base case and all sensitivity analyses for both
QoL outcome measures.
Overall, the economic analyses indicated that there appears to be only a very modest chance that nurses
working according to the competency framework will increase costs and a far greater chance that this will
reduce treatment costs compared with TAU. The data also suggest that such a role was detrimental to
patient care, albeit the impact is small. Such findings might be consistent if the framework role reduced
duplication and unnecessary services, which occasionally left patients less well supported overall.
The origin of the apparent cost-effectiveness also needs to be considered. The raw data reported in
Table 29 showed that there was very little change in total health and social service and societal costs
from baseline to follow-up in the framework arm but a larger increase in these costs in the usual care arm.
This pattern of results is reflected in the relative cost savings in the framework arm reported in Table 30
following bootstrapping and adjustment for baseline variables. Thus, over the course of the trial the costs
rose more for those in the TAU arm than they did for those in the framework arm. The reasons for this are
not clear. One speculative interpretation is that, as a result of being involved in the trial, nurses in both
arms changed their behaviours but that, although the competency framework led nurses in the active arm
to engage in actions that resulted in cost-effective interventions, nurses in the TAU arm, without that set
of guiding principles, made changes that resulted in increased costs. Against this, however, it is noted
that in both arms the, albeit, small number of responses from family carers revealed that most had not
perceived any difference in the treatment received by participants during the intervention period. In
addition, it is hard to see how such an explanation could explain the larger increase in societal costs
during follow-up for those in the TAU arm.
Overall, however, at conventionally accepted WTP thresholds, the competency framework appears to be
cost-effective. Although less clinically effective than usual care, the role appears to be associated with a
reduction in the cost of supporting patients compared with TAU as delivered in this trial, which would
justify its application. Differences in both costs and outcomes were not significant at the 5% level; at a
threshold of £20,000–30,000 per QALY the likelihood that the intervention is cost-effective is 75–80%.
It should be noted that, although our analysis indicates a potential for the competency framework to
reduce costs, it is possible that there are additional costs associated with the implementation of the
competency framework that were not captured within our trial.
Interpretation of the planned subgroup analyses
Although no benefits of the competency framework were observed across the participants randomised to
the active arm as a whole, there was a significant interaction between ELDQoL-SSS score and treatment arm
and level of ID, suggesting a differential response to the intervention according to whether a participant had
a mild to moderate or a severe to profound ID. Thus, for those with a severe to profound ID, there was no
evidence of either treatment being superior, whereas among those with a mild to moderate ID there was a
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trend towards a beneficial effect in the active treatment arm. This possible effect should, however, be
considered with caution as the treatment effect was not significant in either arm.
The EpAID trial is, by some distance, the largest reported study of a nursing intervention related to epilepsy
in adults with an ID and, as far as the authors are aware, no previous study has examined the question of
whether or not there is any relationship between the severity of a person’s ID and the extent to which they
may benefit from more structured nursing input. It is possible that, as people with a severe-to-profound ID
generally have more severe and pervasive brain dysfunction than those with a less severe ID, the capacity
for their epilepsy to improve in response to the use of the competency framework is more limited,
especially as the framework tends to focus on optimising current treatment approaches. Certainly, in any
future research on, or application of, the competency framework, our results suggest that consideration
should be given to the severity of the ID present.
Issues to consider regarding delivery of the interventions
Examination of how the nurses involved in the trial delivered management to the participants suggests
another possible benefit of employing the competency framework. It was observed that, on average, the
nurses in the competency framework arm engaged in five clinical contacts with their patients over the
course of the intervention, compared with an average of seven contacts reported by the nurses delivering
TAU. Given that the outcomes in the two arms of the trial were relatively similar it may be that the use of
the competency framework facilitates more efficient working.
However, when considering this possibility it should also be noted that, although community teams were
randomly allocated to the competency framework and the TAU arms, subsequent examination of the
nurse competencies recorded at baseline indicates that in the control arm there were more ‘novice’ nurses,
with limited previous experience of managing epilepsy in adults with ID, whereas in the experimental arm
there were more nurse prescribers with high levels of relevant prior clinical experience. These differences in
therapist expertise between the arms were taken into account in the analysis of the primary and secondary
end points. However, when examining the pattern of activities engaged in by the nurses during the trial,
it is important to consider the effect that this imbalance could have exerted. For instance, the greater
proportion in the competency framework arm of clinical contacts involving a response to urgent health or
behavioural concerns may have arisen because the nurses in that arm were in general more experienced
and therefore perhaps more likely to deliver such interventions; in teams in which the nurses were less
experienced, such interventions may have been delivered by other members of the multidisciplinary team.
Similarly, the greater proportion in the competency framework arm of contacts involving the prescribing of
AED is likely to relate to the greater number of nurse prescribers working in that arm.
Safety issues
Six participants died between their entry into the trial and the end of the collection of their follow-up data.
In addition, a further two participants died after their involvement in the trial had finished but before their
research sites had been closed. As noted in Chapter 3 (see Safety findings), there was no significant
difference between the arms in the proportion of participants who died.
As stated in Chapter 1 (see Epilepsy and intellectual disability), people with ID and epilepsy have particularly
high rates of death.5 Robertson et al.,78 in a systematic review of 16 studies drawn from eight high-income
countries, observed that mortality rates were higher in those with an ID and epilepsy than in comparable
populations with just one of these conditions. They also noted, as others have done,79 that increased mortality
rates in people who have both an ID and active epilepsy may in part be explained by the observations that
those with a more severe ID are also more likely to have epilepsy than those with milder levels of intellectual
impairment and that people with a more severe ID in general have higher mortality rates.
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For six of the eight participants who died, their death was attributed to a respiratory problem. This is in line
with data from the analysis by Glover and Ayub7 of causes of death in those with an ID, as described on
death certificates for all deaths in England between 2004 and 2008, which found that the most common
cause of death for people with an ID was respiratory disease, reported in 52% of the sample. Although
there are significant limitations of this analysis, in that the authors estimated that only around half the
number of death certificates that they would have expected to mention an ID actually mentioned one,
based on the prevalence of ID in England, it is the largest study of its kind to have analysed these figures.
Overall, no differences were observed between the study arms in the frequency of SAEs. Although in both
arms 16% of the participants were admitted to hospital on at least one occasion, it is already known that
the clinical population under investigation has, as summarised in Chapter 1 (see Epilepsy and intellectual
disability), high rates of morbidity. Hence, in summary, there is no evidence that the use of the competency
framework was associated with morbidity or mortality rates that differed from those seen for TAU.
Qualitative outcomes
As noted earlier, although family carers and paid support workers formed various views about the nurses
with whom they had contact during the trial, there was no evidence that these views were shaped by
which arm of the trial they had been exposed to. However, it is apparent from the data that we collected
that family carers and paid support workers had very few grounds on which to evaluate the service that
they received from nurses, beyond how they felt about an individual nurse; in this trial, in both arms,
it was observed that these respondents were likely to be appreciative of the nurses working with them.
Therefore, although some respondents spoke negatively about past experiences or reported that the nurse
who they saw was not particularly involved in the practicalities of epilepsy management, because the
person concerned also saw a psychiatrist, they lacked sufficient awareness of variations between services
to evaluate the service that they used. Given the uncertainties of epilepsy management, they were also
unable to comment on the effectiveness of a person’s treatment beyond noting – in some cases – that his
or her medication had not been changed for some time.
The nurses interviewed were not asked which arm of the trial they thought that they had been allocated
to. Rather, in this part of the analysis we explored whether or not there were implicit differences in the
nature of the nurses’ responses that could be related to which arm of the trial they had been allocated to.
As noted in Chapter 3, none was found. The impression gained from the nurses’ interviews, supported by
the comments made by family carers and paid support workers, was that, across both arms of the study,
nurses considered that they were able to conscientiously discharge their responsibilities. It is reassuring that
the nurses had this perception. However, from the point of view of the trial we cannot conclude whether
or not those nurses allocated to the competency framework arm thought that their clinical practice had
been changed by the use of the framework. However, given that the trial design involved obscuring from
nurses which arm they were in, and that, in general, they did not, when asked, actually recall any formal
training related to the trial, this is not surprising and it is likely, at least in the small sample of nurses
interviewed, that they did not have expectations that could have biased their performance in the trial
according to which arm they were actually allocated to.
The generalisability of the trial findings
Approach to data analysis
Given the challenges of collecting cost and outcome data in this group of patients, the levels of missing
data were relatively modest. However, the analysis of cost-effectiveness in cluster randomised trials,
with missing data and the potential for baseline differences to influence the results, is challenging.80
We prioritised the need to account for missing data in a principled manner along with adjustment for
any differences in baseline covariates. In the economic analysis we used bootstrapping to quantify the
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uncertainty in costs and outcomes. Such an approach makes no parametric assumptions (although our
adjustment for baseline imbalances did) and captures any correlation between costs and outcomes. However,
this approach did not explicitly allow for the clustering of data in the sampling routine. We addressed this in
the economic analysis with a sensitivity analysis in which we undertook the imputation of missing data first
and then applied a two-stage bootstrap routine to each of the imputed data sets. This latter approach has the
weakness that it did not support adjustment for baseline imbalances in patient covariates. However, the
similarity in the results of the two approaches is encouraging. Hospital costs were limited to costs associated
with epilepsy.
In the course of the analysis, a number of secondary hypotheses were tested. No corrections for multiple
comparisons were made and therefore the results of these tests of the secondary hypotheses should be
considered with caution.
Study blinding
Clinicians in both arms were aware that they were part of a treatment trial and all had received direct
training from a senior nurse. Although those in the TAU arm were not explicitly taught about the
competency framework, they were aware that the focus of the research was on how to manage epilepsy
in people with an ID and epilepsy. As a consequence they may have tried to improve the management
that they provided for patients involved in the study,81 potentially overshadowing the effects of the
intervention. However, the authors are not aware of any clusters in which the nurses delivering treatment
were explicitly aware of what approaches were being compared and which arm they were in.
Variability in clinical services
It has been noted previously that undertaking RCTs of complex interventions in ID services may be
difficult and, in particular, that regional variations in practice contribute to difficulties in evaluating such
interventions.82 In the case of epilepsy management in adults with an ID, variations in practice exist
internationally, as reflected in an earlier exercise to develop international expert consensus-based
guidelines,9 as well as locally.83 However, variability in how epilepsy is managed in this clinical group has
persisted and was one of the key rationales for undertaking the EpAID trial. Nonetheless, as a consequence
of this, although within the competency framework arm the expectation was that this variability would be
reduced, in the TAU arm it is likely that any existing variability between services persisted. It has been
pointed out in other contexts that, when there is such variability, to support generalisability to other clinical
settings, management in the control group should not deviate too much from existing local practices.81
When there are major baseline differences in practice between the participating centres, having limited
numbers of clusters in the arms may also limit generalisability.
In defence of the generalisability of the trial in the face of appreciable baseline variability in service delivery,
the following points may be made. The competency framework acknowledges that there is large variability
in how community ID services operate and in how they are set up to manage epilepsy. The EpAID trial was
designed to test the effects of making use of the competency framework in this real-world environment.
Hence, no structural or personnel changes were made in any of the clinical services in which the research
clusters were located. The research did not examine what happened when a service delivered management
exactly as optimally described in the framework. Rather, it tested the hypothesis that nurses, working as far
as they could towards the goals described by the framework and within the constraints of their existing
service, would improve epilepsy-related outcomes for adults with an ID compared with nurses working
without this set of explicit competency aspirations. The variable nature of pre-existing epilepsy services in the
various sites comprising each arm was in theory taken account of by the random allocation of services to the
treatment arms. This approach had the benefit that the potential value of using the competency framework
could be more readily generalised to the full range of community ID services in England, Scotland and Wales
and that the treatment being trialled did not require the more unrealistic and potentially expensive process
of remodelling CIDTs specifically to enable full delivery of all of the competency aspirations. However, it also
meant that, within the active intervention arm, the extent to which the competency framework was
delivered varied from service to service. This may have reduced the scope for finding significant differences
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between the arms. However, in support of being able to generalise to other ID services, the EpAID trial made
use of cluster randomisation to protect against contamination between arms84 and within each cluster the
nurses managed participants using just one approach. In addition, the recruitment of 17 individual cluster
sites from across England, Scotland and Wales, with each site managed by a different health-care delivery
organisation (NHS trust), optimised the external validity of the trial.
Specific limitations associated with the undertaking of a treatment trial
in adults with an intellectual disability living in the community
Recruitment to the trial proved relatively challenging. This was partly explained by the fact that, not only
did the participants themselves need to be willing – if they had capacity – to consent to participate but,
for the majority who lacked capacity, an appropriate individual also needed to be identified who was able
and willing to act as a consultee (in England and Wales) or guardian, welfare attorney or nearest relative
(in Scotland) and who would then also agree to the trial. To overcome these challenges we worked closely
with the community teams delivering care to this patient group and, through them, aimed to constructively
involve carers, particularly family carers.
The importance of this approach was illustrated in a previous qualitative study of parents of adults with
an ID and epilepsy, which observed that, in their role as gatekeepers to access by health services to their
grown-up children, the extent to which parents facilitated their offspring’s participation in therapeutic
activities depended on the parents’ views, as opposed to the clinicians’ views, of those activities.10
A related and necessary consequence of the ID of all of the trial participants was the key role in the trial
of family carers and/or paid support workers in terms of providing the outcome data. Thus, the outcome
measures depended on the perceptions of these others of the state and progress of the participants and
the outcome measures were selected to be appropriate for completion by these informants.
As the research team were aware of these potential challenges to recruitment, the following steps to
minimise attrition were designed into the trial: (1) participation in the trial resulted in very few active
demands being made on the participants, (2) participants were eligible because they had ongoing seizures,
meaning that they and those supporting them were able to readily identify the potential value of the trial,
(3) participation in the trial did not preclude receipt of any other clinically indicated treatment and (4) the
research team followed a flexible informant-led approach to gathering baseline and follow-up data, with
contacts taking place at times and locations suggested by participants and respondents and with, as far as
possible, contacts being made face-to-face, by telephone or by post, as preferred by respondents.
There are, however, issues that may arise when using telephone contact to complete questionnaires.
Questionnaire interviews conducted over the telephone may have been more readily misunderstood than
face-to-face interviews, even if informants had a copy of the relevant questionnaire in front of them (which
was not always the case). On the other hand, telephone calls may have been more convenient as they were
scheduled around the needs of the respondents, including being able to receive calls during the evening
and at weekends, which is likely to have reduced the risk of a delay in obtaining, or failure to obtain,
baseline or follow-up measures.
Further issues that may have affected the trial relate to the different accommodation and care arrangements
that existed for the participants. In both arms, the great majority of participants lived either in a group home
or with members of their family. However, in the competency framework arm, a slightly higher proportion
of participants lived in a group home than with family, with the opposite pattern observed in the TAU arm.
The potential consequences of these different living arrangements may relate to issues around consent,
data gathering and how paid or family carers might differ in delivering recommended treatments. Informed
consent can be more difficult to gauge when the participant is reliant on others. Participants’ choices may
be limited: they may be used to saying ‘yes’ or ‘no’ to every option, which clouds their ability to make a
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judgement related to informed consent. Furthermore, the researcher may have been seen as an authority
figure, leading to acquiescence by the potential participant.85 With respect to the gathering of baseline and
follow-up data for participants living with family carers, in general a relatively small number of carers were
involved in delivering care, meaning that the informant completing the baseline and follow-up assessments
may have been more likely to be in possession of all of the required information. For the participants living
in a group home, however, where care duties may be split and a larger number of paid support workers
are often involved in delivering care, the quality of information transfer relevant to providing the outcome
measures will have been an important factor. In terms of how paid or family carers might differ in actually
delivering recommended treatments, it is noted in a study from the USA that the adherence to prescribed
AED regimens was greater for those living in a group home than for those living with their family.86
In summary, there are a variety of ways in which living the life of a person with an ID may introduce
challenges into the implementation and interpretation of a clinical trial of a complex intervention.
Conclusions
Differences in outcomes between the competency framework arm and the TAU arm were limited and
associated with various degrees of uncertainty, as quantified in Chapter 3. As noted in Chapter 1, there
is currently a very limited database from which to draw firm conclusions about how best to manage
AED-refractory epilepsy in adults with an ID and, as discussed in earlier sections of this chapter, there are
a range of challenges in undertaking a trial of a complex intervention in this population. The EpAID trial
did not identify any significant clinical differences between the outcomes in the two arms to warrant
changing clinical practice to incorporate the competency framework as it was employed in the trial.
However, although noting both the small effects of the intervention and the limitations of the trial, the
results suggest that the competency framework is likely to be cost-effective when employed in the CIDT
context to inform the management of epilepsy in adults with an ID, although, for the population of adults
with an ID and epilepsy as a whole, there was no clinical benefit compared with TAU.
The observation of a trend towards the use of the competency framework in those with a mild-to-moderate
ID being associated with a small amount of benefit in terms of reducing concerns over seizure severity
suggests that this could usefully be explored in future research. It should also be noted that the EpAID trial
tested the use of the framework in the short term, meaning that the elements of continuing professional
development that are built into the framework were not tested. Nurses with experience in ID and epilepsy
could be well placed to deliver or facilitate the epilepsy management recommended for adults with an ID by
the relevant clinical guidelines.87 Future research will be able to explore the specific value of the competency
framework for those with a mild to moderate ID and the potential for greater long-term benefits arising
from application of the continuing professional development element of the framework.
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Appendix 1 The EpAID trial nurse self-completion
diary version 1.4
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Appendix 2 The EpAID trial Epilepsy and Learning
Disabilities Quality of Life questionnaire version 1.6
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Appendix 3 Safety procedures and adverse events
Reporting processes
It was not expected that there would be any major negative effects on participants resulting from
participating in the EpAID trial. No clinically indicated treatments were withheld in either arm of the trial.
However, SAEs that could have been expected in association with participation in the trial included an
increase in seizure frequency or severity, occurrence of uncontrolled seizures requiring paramedic support
or hospital admission and emergence of AED-related adverse effects.
The PI at each cluster site was responsible for recording all SAEs and reporting them to the chief
investigator, via the trial co-ordinator, on trial SAE forms. The chief investigator then reported all SAEs to
the sponsor. Any SAEs classified as ‘related’ and ‘unexpected’ were to be reported to the main research
ethics committee within 15 days of the chief investigator becoming aware of them.
Adverse events
An adverse event was defined as any untoward medical occurrence in a participant involved in the trial.
Adverse events occurring from time to time in patients participating in this trial in both the TAU arm
and the intervention arm were generally not serious in nature and were not considered significant in
terms of the safety assessment. They were not recorded unless considered serious, as defined in the
following section.
Serious adverse events
A SAE was defined as any untoward medical occurrence that:
l resulted in death
l was life-threatening
l required hospitalisation or prolongation of existing hospitalisation
l resulted in persistent or significant disability or incapacity
l consisted of a genetic abnormality or birth defect
l was otherwise considered medically significant by the investigator.
Serious adverse events that might have been expected in the EpAID trial participants were:
l increased seizure frequency or severity
l the occurrence of uncontrolled seizures requiring paramedic support or hospital admission
l the emergence of AED-related adverse effects
l any event that the treating clinician would expect in a patient with an ID and epilepsy.
For each SAE identified the likely cause, in the view of the local PI (either EpAID trial related or not EpAID
trial related), and the outcome (recovered, recovered with sequelae, ongoing, unknown and death) were
recorded along with the start date, the criteria for designation, expectedness and causality.
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Hospital admissions
In adults with an ID, regardless of whether or not they have epilepsy, there are several causes of hospital
admission that are relatively common and would be expected and unrelated to participation in the trial.
Admissions to hospital for these reasons were not reported as SAEs unless a participant’s local clinical team
considered that an admission primarily for one of the reasons on the list was nevertheless directly or
indirectly associated with the participant’s involvement in the trial. These causes of hospital admission are:
l constipation
l complications of diabetes mellitus
l respiratory infections
l asthma
l cellulitis
l dental infections
l kidney disease.
Serious adverse events reported
The complete list of adverse events reported is provided in Table 32.
TABLE 32 Complete list of SAEs reported
Site
Person
identification
number SAE Consequence
Caused by
EpAID trial Outcome
01 1 Admitted for prolonged seizures Hospitalisation No Unknown
01 4 Admitted for prolonged seizures Hospitalisation No Unknown
01 12 Hospitalised for management of deep-vein thrombosis Hospitalisation No Resolved
01 12 Admitted following 2–3 weeks of poor eating and
drinking
Hospitalisation No Unknown
01 19 Admitted for uncontrolled seizures secondary to poor
food and fluid intake and medication compliance
Hospitalisation No Unknown
02 2 Admitted for back pain and laboured breathing Hospitalisation No Resolved
02 3 Admitted because of coughing and general lethargy
alongside associated foul-smelling urine
Hospitalisation No Resolved
02 3 Admitted following five seizures overnight Hospitalisation No Resolved
02 4 Admitted because of increased seizure activity Hospitalisation No Resolved
02 6 Percutaneous endoscopic gastrostomy tube had fallen
out overnight. Admitted for re-siting. Discharged same
day
Hospitalisation No Resolved
02 10 Admitted to hospital with community-acquired
pneumonia
Hospitalisation No Resolved
02 10 Admitted to hospital following repeated seizures
despite rescue medication
Hospitalisation No Resolved
02 14 Admitted for mental health breakdown Hospitalisation No Ongoing
02 21 Pneumonia and multiple organ failure Death No Death
02 21 Constipation Hospitalisation No Resolved
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TABLE 32 Complete list of SAEs reported (continued )
Site
Person
identification
number SAE Consequence
Caused by
EpAID trial Outcome
04 1 Participant admitted as had been difficult to rouse and
was not taking food or fluids
Hospitalisation No Unknown
04 2 Seizures at respite care, rescue medication
administered, further seizures and raised temperature
Hospitalisation No Resolved
04 2 Cluster of seizures Hospitalisation No Resolved
04 3 Unwitnessed seizure/fall Hospitalisation No Resolved
05 5 Previously diagnosed with malignant tumour. Epilepsy
relapsed as could not tolerate medication
Hospitalisation No Unknown
05 5 Inoperable abdominal tumour Other No Unknown
05 5 Patient had a terminal illness Death No Death
05 22 Prolonged seizures that required hospitalisation to
stabilise
Hospitalisation No Resolved
06 5 Routine change of baclofen, no complications Hospitalisation No Resolved
06 5 High temperature with possible underlying renal
infection
Hospitalisation No Resolved
06 11 Admitted to hospital because of breathing difficulties
arising from chest infection
Hospitalisation No Resolved
07 19 Mini stroke Hospitalisation No Resolved
07 19 Participant fell and hit head. Admitted but no cause
found
Hospitalisation No Unknown
07 19 Participant fell and hit head. Admitted but no cause
found
Hospitalisation No Unknown
07 19 Participant fell downstairs while carrying a bag of
rubbish and sustained small fracture to the skull
Hospitalisation No Unknown
08 13 Death from natural causes: aspiration of blood
following bleeding oesophagitis
Death Yes Death
08 14 Seizures continued after administration of rescue
medication
Hospitalisation No Resolved
08 14 Seizures continued after administration of rescue
medication
Hospitalisation No Resolved
08 16 Admitted for low pulse rate and hypertension; treated
for infection
Hospitalisation No Unknown
08 16 Treated for infection Hospitalisation No Resolved
08 16 Hospitalisation for re-siting of percutaneous
endoscopic gastrostomy tube
Hospitalisation No Resolved
08 16 Admitted for treatment of chest infection Hospitalisation No Resolved
08 17 Admitted for further administration of rescue
medication
Hospitalisation No Unknown
08 17 Admitted for administration of further rescue
medication to control seizures
Hospitalisation No Resolved
09 1 Admitted to hospital following blood test. Patient
aspirated, resulting in pneumonia and collapsed lung
Death No Death
continued
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TABLE 32 Complete list of SAEs reported (continued )
Site
Person
identification
number SAE Consequence
Caused by
EpAID trial Outcome
09 2 Fell during seizure, sustained a broken leg in two
places
Hospitalisation No Unknown
09 5 In hospital since November 2015, death from
respiratory causes
Death No Death
09 5 Feeding tube dislodged, pneumonia delayed surgical
re-implantation
Other No Ongoing
09 9 Admitted to hospital because of prolonged clonic
seizures
Hospitalisation No Unknown
09 9 Long clonic seizure, GP thought patient was
dehydrated
Hospitalisation No Resolved
09 14 Hospitalisation after seizure during which the
participant fell to the floor and broke an ankle
Hospitalisation No Unknown
09 20 Lump in breast Other No Unknown
11 5 Multiple infections, acute bronchiolitis, enterocolitis
(Clostridium difficile), urinary tract infection
Hospitalisation No Ongoing
11 5 Attended A&E for low oxygen saturation. Suffered
respiratory arrest
Death No Death
11 10 Head injury following a fall after a seizure Hospitalisation No Resolved
13 13 Admitted because of epilepsy episode but diagnosed
with a chest infection
Hospitalisation No Resolved
15 29 18 seizures in 24 hours, which did not respond to
rescue medication
Hospitalisation No Resolved
15 29 Assumed post-ictal state Hospitalisation No Resolved
16 5 Multiple seizures, chest infection, constipation Hospitalisation Response not
provided by
respondent
Ongoing
16 5 Continuation of condition Hospitalisation Response not
provided by
respondent
Ongoing
16 5 Increase in seizures, bowel perforation Hospitalisation Response not
provided by
respondent
Ongoing
16 12 Participant died in her sleep of a heart attack Death Response not
provided by
respondent
Death
16 16 Diagnosis of community-acquired pneumonia –
CURB-65 pneumonia severity score of 2, chronic type 2
respiratory failure
Hospitalisation No Resolved
16 16 Admitted to hospital because of a cough. Diagnosis
was community-acquired pneumonia
Hospitalisation Response not
provided by
respondent
Ongoing
16 16 Admitted to hospital with a chest infection. Died of
pneumonia
Death Response not
provided by
respondent
Death
17 12 Participant attended A&E because of uncontrollable
pain. Changes made to insulin medication
Hospitalisation No Ongoing
CURB-65, confusion, uraemia, respiratory rate, blood pressure, age ≥ 65 years.
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Appendix 4 Scoring instructions for the Epilepsy
and Learning Disabilities Quality of Life questionnaire
Scoring instructions for the 4 subscales of the re-validated version 
of ELDQOL 
 
 
A. Seizure Severity Scale (Qs. 1 – 14) 
 
 
Qs. 1, 5, 7, 8, 9, 10, 11, 13 
 
Reverse the individual item scoring so that  
 
1 = 4 
2 = 3 
3 = 2 
4 =1 
5 - define as a missing value so that it is not included in the calculation  
      of the scale score 
 
Qs. 4, 12    
 
Reverse the individual item scoring so that  
 
1 = 4 
2 = 3 
3 = 2 
4 =1 
5 = 0 
6 - define as a missing value 
 
Qs. 2, 14 
 
5 - Define 5 as a missing value. 
Other scores unchanged. 
  
Qs. 3, 6    
 
5 = 0 
Define 6 as a missing value. 
Other scores unchanged 
 
Total scale score range = 10-56  
 
 
 
B. Side-effects Profile  (Qs. 17 & 18) (Only items in Q.18 used to compute sub-scale.) 
 
Reverse the individual scoring of each of the 19 items in Q.18 so that: 
 
1 = 4 
2 = 3 
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3 = 2 
4 =1 
5 - define as a missing value 
 
Any additional problems itemised by respondents should be recorded, but are not added to 
the total scale score. 
 
Total scale score range = 19-76 
 
 
  
C. Behaviour (Qs. 19 – 27) 
 
Qs.19, 24, 25, 26 
 
 Define 5 as a missing value 
 Other scores unchanged 
 
Qs. 20, 21, 27  
 
Reverse scoring so that: 
 
1 = 4 
2 = 3 
3 = 2 
4 =1 
5 - define as a missing value 
 
Qs.22, 23  
 
Recode so that: 
 
 5 = 4 
 6 – define as a missing value 
 Other scores unchanged 
 
Total scale score range = 9-36 
 
 
 
D. Mood Scale (Q. 28) 
 
Reverse scoring of negative items (aggressive, irritable, tearful, hyperactive, sad, agitated, 
restless, tantrum-prone, frustrated, withdrawn), so that: 
 
1 = 4 
2 = 3 
3 = 2 
4 =1 
5 - define as a missing value 
 
Total Scale score range = 16-64 
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Appendix 5 Missing data
TABLE 33 Epilepsy and Learning Disabilities Quality of Life SSS missingness
Baseline Follow-up
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Present Present 100/184 54.3 72/128 56.3 172/312 55.1
Present No seizures (4 weeks) 26/184 14.1 16/128 12.5 42/312 13.5
Present Missing 10/184 5.4 14/128 10.9 24/312 7.7
< 50% answered No seizures (4 weeks) 1/184 0.5 1/128 0.8 2/312 0.6
< 50% answered Missing 0/184 0.0 1/128 0.8 1/312 0.3
No seizures (4 weeks) Present 13/184 7.1 10/128 7.8 23/312 7.4
No seizures (4 weeks) No seizures (4 weeks) 21/184 11.4 11/128 8.6 32/312 10.3
No seizures (4 weeks) Missing 6/184 3.3 0/128 0.0 6/312 1.9
Missing Present 0/184 0.0 1/128 0.8 1/312 0.3
Missing Missing 7/184 3.8 2/128 1.6 9/312 2.9
TABLE 34 Epilepsy and Learning Disabilities Quality of Life AED side effects missingness
Baseline Follow-up
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Present Present 82/184 44.6 62/128 48.4 144/312 46.2
Present < 50% answered 5/184 2.7 3/128 2.3 8/312 2.6
Present No seizures (4 weeks) 18/184 9.8 17/128 13.3 35/312 11.2
Present Missing 9/184 4.9 14/128 10.9 23/312 7.4
< 50% answered Present 7/184 3.8 4/128 3.1 11/312 3.5
< 50% answered < 50% answered 6/184 3.3 3/128 2.3 9/312 2.9
< 50% answered No seizures (4 weeks) 9/184 4.9 0/128 0.0 9/312 2.9
< 50% answered Missing 1/184 0.5 1/128 0.8 2/312 0.6
No seizures (4 weeks) Present 10/184 5.4 10/128 7.8 20/312 6.4
No seizures (4 weeks) < 50% answered 3/184 1.6 0/128 0.0 3/312 1.0
No seizures (4 weeks) No seizures (4 weeks) 21/184 11.4 11/128 8.6 32/312 10.3
No seizures (4 weeks) Missing 6/184 3.3 0/128 0.0 6/312 1.9
Missing Present 0/184 0.0 1/128 0.8 1/312 0.3
Missing Missing 7/184 3.8 2/128 1.6 9/312 2.9
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TABLE 35 Epilepsy and Learning Disabilities Quality of Life behaviour missingness
Baseline Follow-up
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Present Present 99/184 53.8 71/128 55.5 170/312 54.5
Present < 50% answered 0/184 0.0 1/128 0.8 1/312 0.3
Present No seizures (4 weeks) 27/184 14.7 17/128 13.3 44/312 14.1
Present Missing 10/184 5.4 15/128 11.7 25/312 8.0
< 50% answered Present 1/184 0.5 0/128 0.0 1/312 0.3
No seizures (4 weeks) Present 13/184 7.1 10/128 7.8 23/312 7.4
No seizures (4 weeks) No seizures (4 weeks) 21/184 11.4 11/128 8.6 32/312 10.3
No seizures (4 weeks) Missing 6/184 3.3 0/128 0.0 6/312 1.9
Missing Present 0/184 0.0 1/128 0.8 1/312 0.3
Missing Missing 7/184 3.8 2/128 1.6 9/312 2.9
TABLE 36 Epilepsy and Learning Disabilities Quality of Life mood missingness
Baseline Follow-up
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Present Present 97/184 52.7 72/128 56.3 169/312 54.2
Present < 50% answered 1/184 0.5 0/128 0.0 1/312 0.3
Present No seizures (4 weeks) 27/184 14.7 17/128 13.3 44/312 14.1
Present Missing 10/184 5.4 15/128 11.7 25/312 8.0
< 50% answered Present 1/184 0.5 0/128 0.0 1/312 0.3
< 50% answered < 50% answered 1/184 0.5 0/128 0.0 1/312 0.3
No seizures (4 weeks) Present 11/184 6.0 10/128 7.8 21/312 6.7
No seizures (4 weeks) < 50% answered 2/184 1.1 0/128 0.0 2/312 0.6
No seizures (4 weeks) No seizures (4 weeks) 21/184 11.4 11/128 8.6 32/312 10.3
No seizures (4 weeks) Missing 6/184 3.3 0/128 0.0 6/312 1.9
Missing Present 0/184 0.0 1/128 0.8 1/312 0.3
Missing Missing 7/184 3.8 2/128 1.6 9/312 2.9
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TABLE 38 Modified Carer Strain Index missingness
Baseline Follow-up
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Present Present 37/165 22.4 30/118 25.4 67/283 23.7
Present Missing 12/165 7.3 19/118 16.1 31/283 11.0
Missing Present 0/165 0.0 2/118 1.7 2/283 0.7
Missing Missing 116/165 70.3 67/118 56.8 183/283 64.7
TABLE 39 Covariate missingness
Variable
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Age 7/184 3.8 2/128 1.6 9/312 2.9
Accomodation 7/184 3.8 6/128 4.7 13/312 4.2
Level of ID 11/184 6.0 21/128 16.4 32/312 10.3
Deprivation Index 5/184 2.7 2/128 1.6 7/312 2.2
Number of tonic–clonic seizures 11/184 6.0 10/128 7.8 21/312 6.7
TABLE 37 Tonic–clonic seizures missingness
Baseline Follow-up
Treatment arm
OverallActive TAU
n/N % n/N % n/N %
Present Present 153/184 83.2 98/128 76.6 251/312 80.4
Present Missing 20/184 10.9 20/128 15.6 40/312 12.8
Missing Present 3/184 1.6 2/128 1.6 5/312 1.6
Missing Missing 8/184 4.3 8/128 6.3 16/312 5.1
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Appendix 6 Community intellectual disability team
epilepsy service availability questionnaire version 1
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